6'-cyano-modified locked nucleoside, nucleotide, and nucleic acid polymer

By preparing 6'-cyano-modified nucleosides, nucleotides, and nucleic acid polymers with R or S configurations, the hepatotoxicity and nephrotoxicity of nucleic acid drugs have been solved, improving the safety and efficacy of nucleic acid drugs and achieving highly efficient and low-toxicity nucleic acid chemical modification.

WO2024234728A1PCT designated stage expired Publication Date: 2024-11-21ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/074208
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-01-26
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing nucleic acid drugs exhibit liver and kidney toxicity issues after chemical modification, and the differences in drug properties caused by C6'-epimers have not been effectively addressed, affecting their application in nucleic acid drugs.

Method used

This invention provides methods for preparing 6'-cyano-modified nucleosides, nucleotides, and nucleic acid polymers with R or S configurations. Through specific chemical synthesis routes, 6'-cyano-modified nucleosides with high yields are synthesized, reducing their interaction with intracellular proteins and improving nuclease tolerance.

Benefits of technology

It significantly reduces the interaction between nucleic acid polymers and intracellular proteins, improves nuclease tolerance, reduces apoptosis effects, and enhances the safety and efficacy of nucleic acid drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024074208_21112024_PF_FP_ABST
    Figure CN2024074208_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to the field of biotechnology, and provided thereby are a 6'-cyano-modified locked nucleoside, nucleotide, and nucleic acid polymer. The 6'-cyano-modified locked nucleoside provided by the present invention is of an R configuration or an S configuration, and is further modified to obtain the nucleotide and the nucleic acid polymer. It has been found by the inventors via study that the 6'-cyano-modified nucleic acid polymer has better nuclease tolerance than unmodified nucleic acid polymers or other modified nucleic acid polymers, thus reducing or regulating interaction between the nucleic acid polymer and intracellular proteins. Therefore, the 6'-cyano-modified locked nucleoside, nucleotide, and nucleic acid polymer provided by the present invention have significant application value in the aspect of nucleic acid drugs. Preparation methods for the locked nucleoside, nucleotide, and nucleic acid polymer provided by the present invention are efficient, stable, and practical, and are compatible with various substituted or unsubstituted bases.
Need to check novelty before this filing date? Find Prior Art

Description

6'-Cyano-modified locked nucleosides, nucleotides, and nucleic acid polymers

[0001] This application claims priority to the Chinese patent application filed with the China Patent Office on May 18, 2023, with application number CN202310565102.7 and invention name “6'-cyano-modified locked nucleosides, nucleotides and nucleic acid polymers”, the entire contents of which are incorporated by reference into this application. Technical Field

[0002] The present invention relates to the field of biotechnology, in particular to a 6'-cyano-modified locked nucleoside, nucleotide and nucleic acid polymer. Background Art

[0003] Nucleic acid drugs are at the forefront of biomedical development and are the third largest type of drug after small molecule drugs and protein drugs. Nucleic acid drugs mainly include antisense nucleic acids (ASOs) and small interfering RNAs (siRNAs). Compared with traditional small molecule and protein drugs, they have the advantages of rapid design, universal targets, high specificity, intracellular function, and relatively rapid synthesis. They are of great value in the treatment of many chronic, refractory major diseases and rare diseases that are difficult to drug at protein targets. As of 2022, 15 nucleic acid drugs have been approved worldwide (10 ASOs and 5 siRNAs), and more than 400 nucleic acid drugs are in clinical trials.

[0004] However, on the one hand, the drugability of unchemically modified oligonucleotide drugs is generally suboptimal. They have poor drugability properties, such as poor stability and susceptibility to nuclease degradation; high polarity, difficulty entering cells, poor distribution characteristics; and poor binding affinity for target mRNA. To achieve clinical efficacy, oligonucleotides must undergo chemical modification, and all marketed nucleic acid drugs use corresponding nucleic acid chemical modifications. On the other hand, chemically modified antisense nucleic acid drugs can cause toxicity to highly exposed organs (liver and kidneys) to a certain extent. In particular, chemically modified nucleic acid drugs such as locked nucleic acids (LNA) with high affinity on the phosphorothioate (PS) backbone and constrained ethyl locked nucleic acids (cEt-LNA) may cause hepatotoxicity or nephrotoxicity, including significantly elevated liver ALT and AST levels, or necrosis, degeneration / regeneration of renal tubules. Therefore, efficient and safe new-generation nucleic acid chemical modification technology remains a key technology and bottleneck in the development of nucleic acid drugs.

[0005] In recent years, significant progress has been made in understanding the toxicity mechanisms of antisense nucleic acid drugs (Nucleic Acids Res. 2016, 44, 3892; Nature Biotech., 2017, 35, 230; Nucleic Acids Res. 2018, 46, 2204; Nature Biotech., 2019, 37, 640; Nucleic Acids Res. 2019, 47, 10865; J. Am. Chem. Soc., 2020, 142, 14754; J. Am. Chem. Soc. 2020, 142, 7456). Studies have shown that the primary toxicity mechanism of antisense nucleic acid drugs is that chemically modified sulfhydryl antisense nucleic acid drugs (PS-ASOs) bind to and interfere with the subcellular distribution of intracellular proteins (such as P54nrb), thereby inducing cell apoptosis and producing toxicity. At the same time, toxicity is positively correlated with ASO-protein binding ability: the stronger the binding force, the greater the potential toxicity. This binding ability is closely related to the water solubility (LogS) of the chemically modified structure: the stronger the hydrophobic interaction, the greater the binding affinity. Experimental results show that the affinity of 2'-methoxyethyl (2'-MOE) for intracellular proteins is 30 times lower than that of 2'-fluoro (2'-F). Therefore, the interaction between antisense nucleic acids and proteins has become a determining factor in the efficacy of antisense nucleic acid drugs. Structure determines properties. To develop efficient and safe new nucleic acid chemical modification structures, the inventors previously disclosed a novel cyano-locked nucleic acid (CN-LNA) modification structure (ZL 20190914759.3), which exhibits high nuclease resistance, as well as good target gene affinity and selectivity. At the same time, further chemical property calculations (Chemdraw calculations) showed that CN-LNA has good hydrophilicity, with a LogS value of -0.032, which is approximately 2 times, 4 times, and 20 times that of the commonly used 2'-methoxyethyl (MOE, LogS value of -0.073), locked nucleic acid (LNA, LogS value of -0.122), and 2'-fluoro (LogS value of -0.661), respectively. It has the potential to reduce the binding affinity of PS-ASO to intracellular proteins, thereby reducing the impact on intracellular protein distribution, reducing toxicity, and improving therapeutic effects.

[0006] However, the previously disclosed CN-LNA synthesis method cannot stereoselectively synthesize the R and S configurations of C6'-isomers, and fails to further explain the differences in the druggability of the C6'-isomers with their modified nucleic acids, which cannot meet the needs of establishing a new generation of efficient and low-toxic nucleic acid chemical modification technology.

[0007] In view of this, the present invention is proposed.

[0008] Summary of the Invention

[0009] The first object of the present invention is to provide R- or S-configuration 6'-cyano-modified locked nucleosides, nucleotides, and nucleic acid polymers.

[0010] The second object of the present invention is to provide a method for preparing R- or S-configuration 6'-cyano-modified locked nucleosides, nucleotides and nucleic acid polymers. The preparation method is simple, has a high yield, and can solve at least one of the above problems.

[0011] The third object of the present invention is to provide the use of the above-mentioned nucleic acid polymer in the preparation of nucleic acid diagnostic agents or nucleic acid therapeutic agents.

[0012] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are adopted:

[0013] In a first aspect, the present invention provides a 6'-cyano modified locked nucleoside, wherein the 6'-cyano modified locked nucleoside is selected from a compound having a structure as shown in Formula 1, a salt thereof, or an isomer thereof:

[0014] In formula 1: Bx is selected from substituted or unsubstituted: adenine, guanine, thymine, cytosine, uracil or their respective salts;

[0015] Z is a cyano group;

[0016] W1 and W2 are independently selected from H or a hydroxy protecting group; the hydroxy protecting group includes: the hydroxy protecting group is selected from but not limited to: acetyl, tert-butyl, tert-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, di(2-acetoxyethoxy)methyl, 2-trimethylsilylethyl, trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tritylsilyl, [(triisopropylsilyl)oxy]methyl, benzoylformate, chloroacetyl, trichloroacetyl, trifluoroacetyl, pivaloyl, benzoyl, p-phenylbenzoyl, 9-fluorenylmethyl carbonate, methanesulfonate, p-toluenesulfonate, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, 1(2-fluorophenyl)-4-methoxypiperidin-4-yl, 9-phenylxanthin-9-yl, 9-(p-methoxyphenyl)xanthin-9-yl, or 2-naphthylmethyl;

[0017] The isomers include: 6'-cyano modified locked nucleoside with the Z group in R configuration, the structural formula is Or the Z group is in the S-configuration 6'-cyano modified locked nucleoside, the structural formula is

[0018] In a second aspect, the present invention provides a nucleotide comprising a 3'-active phosphorus group derivative of the above-mentioned 6'-cyano modified locked nucleoside;

[0019] The active phosphorus group is selected from the group consisting of phosphoramidites, derivatives of phosphoramidites, H-phosphates, derivatives of H-phosphates, phosphotriesters, and derivatives of phosphotriesters.

[0020] As a further technical solution, the nucleotide is selected from a compound having a structure as shown in Formula 2, a salt thereof, or an isomer thereof:

[0021] In formula 2: the types of Bx, W2 and Z are the same as those in formula 1;

[0022] The isomers include: nucleotides with the Z group in the R configuration, the structural formula is Or the nucleotide with Z group in S configuration has the structural formula

[0023] In a third aspect, the present invention provides use of the above-mentioned nucleotides in reducing the interaction between nucleic acid polymers and intracellular proteins or in preparing a drug for reducing the interaction between nucleic acid polymers and intracellular proteins.

[0024] In a fourth aspect, the present invention provides a nucleic acid polymer having a monomer having a structure as shown in Formula 3:

[0025] In formula 3, Bx is selected from substituted or unsubstituted: adenine, guanine, thymine, cytosine, uracil or their respective salts;

[0026] Z is a cyano group;

[0027] W3 and W4 are each independently H, a hydroxyl protecting group, or an internucleoside linking group that connects the monomer to the rest of the nucleic acid polymer; and at least one of W3 and W4 is an internucleoside linking group that connects the monomer to the rest of the nucleic acid polymer;

[0028] The hydroxy protecting groups include: acetyl, tert-butyl, tert-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, bis(2-acetoxyethoxy)methyl, 2-trimethylsilylethyl, trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tritylsilyl , [(triisopropylsilyl)oxy]methyl, benzoylformate, chloroacetyl, trichloroacetyl, trifluoroacetyl, pivaloyl, benzoyl, p-phenylbenzoyl, 9-fluorenylmethyl carbonate, methanesulfonate, p-toluenesulfonate, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, 1(2-fluorophenyl)-4-methoxypiperidin-4-yl, 9-phenylxanthin-9-yl, 9-(p-methoxyphenyl)xanthin-9-yl, or 2-naphthylmethyl.

[0029] As a further technical solution, the monomers include: monomers in which the Z group is in R configuration, with the structural formula Or the monomer with Z group in S configuration has the structural formula

[0030] As a further technical solution, the nucleic acid polymer is ribonucleic acid, deoxyribonucleic acid or a copolymer of ribonucleotides and deoxyribonucleotides.

[0031] In a fifth aspect, the present invention provides the use of the above-mentioned nucleic acid polymer in the preparation of a nucleic acid diagnostic agent or a nucleic acid therapeutic agent.

[0032] In a sixth aspect, the present invention provides a method for synthesizing a C6'-cyano modified nucleoside of R configuration or S configuration, wherein the C6'-cyano modified nucleoside of R configuration is The synthesis method comprises: Isomerization of terminal olefins to obtain Then, a dihydroxylation reaction was performed to obtain Then, the aldehyde compound is obtained through oxidative cleavage reaction. Finally The aldehyde group of the nucleoside was converted into a cyano group to obtain a C6'-position cyano-modified nucleoside with R configuration.

[0033] S-configuration C6'-position cyano-modified nucleoside The synthesis method comprises: Isomerization of terminal olefins to obtain Then, a dihydroxylation reaction was performed to obtain Then, aldehyde compounds are obtained through oxidative cleavage reaction. Finally The aldehyde group of the nucleoside was converted into a cyano group to synthesize an S-configuration C6' cyano-modified nucleoside.

[0034] wherein Bx is selected from substituted or unsubstituted adenine, guanine, thymine, cytosine, uracil or their respective salts.

[0035] As a further technical solution, the The synthesis method comprises: The mesylation reaction, debonding reaction and acetylation reaction were carried out in sequence to obtain Then, glycosylation reaction and nucleophilic substitution reaction were performed to synthesize the R configuration

[0036] described The synthesis method comprises: The mesylation reaction, debonding reaction and acetylation reaction were carried out in sequence to obtain Then glycosylation reaction and nucleophilic substitution reaction are carried out to synthesize the S configuration

[0037] The glycosidation reaction is as follows: under the condition of an activator, The method comprises reacting with thymine, N6-benzoyl adenine or 6-chloroguanine at 50-100° C., wherein the activating agent comprises BSA and TMSOTf, and the reaction medium comprises acetonitrile, 1,2-dichloroethane or toluene.

[0038] As a further technical solution, the S configuration The synthesis method comprises: 5-O-(tert-butyldiphenylsilyl)-4-C-hydroxymethyl-1,2-O-isopropylidene-3-O-(2-naphthylmethyl)-α-D-ribofuranose The primary alcohol is oxidized to an aldehyde group, and then the aldehyde group undergoes an allylation reaction to obtain the S configuration.

[0039] Preferably, the R configuration The synthesis method comprises: The secondary alcohol is oxidized to a ketone, and then the ketone is reduced to a secondary alcohol to obtain the R configuration.

[0040] In the process of reducing the ketone to the secondary alcohol, the reducing agent used includes at least one of lithium aluminum hydride, lithium borohydride, lithium chloride or sodium borohydride, the reaction medium includes at least one of dichloromethane, tetrahydrofuran, methanol or ethanol, and the reaction temperature is between -78°C and 0°C.

[0041] Preferably, the reaction of reducing ketone to secondary alcohol is: using sodium borohydride and lithium chloride as reducing agents, tetrahydrofuran and methanol as solvents, and reacting at -40-0°C.

[0042] As a further technical solution, the catalyst for the isomerization of the terminal olefins includes a ruthenium catalyst, a palladium catalyst, a rhodium catalyst or an iridium catalyst, preferably tris(triphenylphosphine)carbonylruthenium(II) hydrochloride;

[0043] The reaction medium for the terminal olefin isomerization comprises methanol, ethanol, n-butanol or toluene, preferably ethanol;

[0044] The reaction temperature of the terminal olefin isomerization is 60-100°C, preferably 60-80°C;

[0045] The reaction time of the terminal olefin isomerization is 12-72 hours.

[0046] In a seventh aspect, the present invention provides a method for synthesizing a C6'-position cyano-locked nucleic acid T phosphoramidite monomer of R configuration or S configuration, the method for synthesizing a C6'-position cyano-locked nucleic acid T phosphoramidite monomer of R configuration comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the R configuration.

[0047] The synthesis method of the S-configuration C6'-position cyano-locked nucleic acid T phosphoramidite monomer comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the S configuration.

[0048] In an eighth aspect, the present invention provides a method for synthesizing a C6'-position cyano-locked nucleic acid A phosphoramidite monomer of R configuration or S configuration, the method for synthesizing a C6'-position cyano-locked nucleic acid A phosphoramidite monomer of R configuration comprises: The bases are protected to obtain Then the 3'-hydroxyl and 5'-hydroxyl groups are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the R configuration.

[0049] The synthesis method of the S-configuration C6'-position cyano-locked nucleic acid A phosphoramidite monomer comprises: The bases are protected to obtain Then the 3'-hydroxyl and 5'-hydroxyl groups are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the S configuration.

[0050] In a ninth aspect, the present invention provides a method for synthesizing a C6'-position cyano-locked nucleic acid G phosphoramidite monomer of R configuration or S configuration, the method for synthesizing a C6'-position cyano-locked nucleic acid G phosphoramidite monomer of R configuration comprises: Demethylation of the methoxy group yields Then base protection is performed to obtain Then the 3'-hydroxyl and 5'-hydroxyl groups are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the R configuration.

[0051] The synthesis method of the S-configuration C6'-position cyano-locked nucleic acid G phosphoramidite monomer comprises: Demethylation of the methoxy group yields Then base protection is performed to obtain Then the 3'-hydroxyl and 5'-hydroxyl groups are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the S configuration.

[0052] In a tenth aspect, the present invention provides a method for synthesizing an R-configuration or S-configuration C6'-position cyano-locked nucleic acid C phosphoramidite monomer, and the preparation method of the R-configuration C6'-position cyano-locked nucleic acid C phosphoramidite monomer comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain Then the 5'-hydroxyl group was protected by DMTr to obtain The 3'-hydroxyl group is then silanized and the carbonyl group is converted into an amino group to obtain Then base protection is performed and the 3'-hydroxyl group is deprotected to obtain Finally, the 3'-hydroxyl group was phosphoramidated to obtain the R configuration.

[0053] The preparation method of the S-configuration C6'-position cyano-locked nucleic acid C phosphoramidite monomer comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain Then the 5'-hydroxyl group was protected by DMTr to obtain The 3'-hydroxyl group is then silanized and the carbonyl group is converted into an amino group to obtain Then base protection is performed and the 3'-hydroxyl group is deprotected to obtain Finally, the 3'-hydroxyl group was phosphoramiditized to obtain the S configuration.

[0054] In an eleventh aspect, the present invention provides a method for synthesizing a nucleic acid polymer, wherein monomers are polymerized to prepare a nucleic acid polymer;

[0055] The monomer includes the 6'-cyano modified locked nucleoside or the nucleotide.

[0056] Compared with the prior art, the present invention has the following beneficial effects:

[0057] The 6'-cyano-modified locked nucleosides provided by the present invention are in the R or S configuration, and are further modified to obtain nucleotides and nucleic acid polymers. The inventors have found that 6'-cyano-modified nucleic acid polymers have better nuclease resistance than unmodified or other modified nucleic acid polymers, reduce or regulate the interaction between nucleic acid polymers and intracellular proteins, and in terms of improving the nuclease resistance of nucleic acid polymers and reducing the interaction between nucleic acid polymers and intracellular proteins, 6'-cyano-modified nucleic acid polymers with the S configuration are more significant than those with the R configuration. Therefore, the 6'-cyano-modified locked nucleosides, nucleotides, and nucleic acid polymers provided by the present invention have significant application value in nucleic acid drugs.

[0058] The present invention provides a universal preparation method for the above-mentioned R-configuration or S-configuration 6'-cyano-modified locked nucleosides, nucleotides and nucleic acid polymers. The preparation method is stable, efficient and has a high yield.

[0059] In addition, compared with LNA modification, the CN-LNA modified nucleic acid sequence obtained by the synthesis method of the present invention can significantly reduce the interference with intracellular protein distribution and reduce the effect of inducing cell apoptosis, thus having significant advantages in the development of efficient and safe nucleic acid drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] In order to more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the specific embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0061] Figure 1 is a mass spectrum of nucleic acid ON1;

[0062] FIG2 is a mass spectrum of nucleic acid ON2;

[0063] FIG3 is a mass spectrum of nucleic acid ON3;

[0064] Figure 4 is a 60× image showing the aggregation of paraplakin P54nrb induced by ON1, ON2, and ON3;

[0065] Figure 5 shows the results of Caspase 3 / 7 activity

[0066] FIG6 is a mass spectrum of nucleic acid ON4;

[0067] FIG7 shows the enzymatic stability of 5′-d(TTTTTTTTT)-3′ to snake venom phosphodiesterase (SVPDE);

[0068] FIG8 is a crystal structure diagram of S-6′-CN-LNA-T monomer (Compound 36). DETAILED DESCRIPTION

[0069] Below in conjunction with embodiment and example, embodiment of the present invention is described in detail, but those skilled in the art will appreciate that the following embodiment and example are only used to illustrate the present invention, and should not be considered as limiting the scope of the present invention. Based on the embodiment in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work premise all fall within the scope of protection of the present invention. Unspecified conditions are carried out according to the conditions of normal conditions or manufacturer's recommendations. Reagents used or instruments not specified by the manufacturer are conventional products that can be purchased commercially.

[0070] The term "nucleic acid polymer" may refer to any nucleic acid molecule, including but not limited to DNA, RNA, and hybrids thereof, including but not limited to single-stranded and double-stranded nucleic acids. The number of nucleotides polymerized to form a nucleic acid may be two, three, or more, and may be an oligonucleotide with fewer than 20 nucleotides or a polymer with more than 20 nucleotides.

[0071] In a first aspect, the present invention provides a 6'-cyano modified locked nucleoside, wherein the 6'-cyano modified locked nucleoside is selected from a compound having a structure as shown in Formula 1, a salt thereof, or an isomer thereof:

[0072] In formula 1: Bx is selected from substituted or unsubstituted: adenine, guanine, thymine, cytosine, uracil or their respective salts;

[0073] Z is a cyano group;

[0074] W1 and W2 are independently selected from H or a hydroxyl protecting group; the hydroxyl protecting group is selected from, but not limited to, acetyl, tert-butyl, tert-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, di(2-acetoxyethoxy)methyl, 2-trimethylsilylethyl, trimethylsilyl, triethylsilyl, tert-butyldimethylsilane methyl, tert-butyldiphenylsilyl, tritylsilyl, [(triisopropylsilyl)oxy]methyl, benzoylformate, chloroacetyl, trichloroacetyl, trifluoroacetyl, pivaloyl, benzoyl, p-phenylbenzoyl, 9-fluorenylmethyl carbonate, methanesulfonate, p-toluenesulfonate, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, 1(2-fluorophenyl)-4-methoxypiperidin-4-yl, 9-phenylxanthin-9-yl, 9-(p-methoxyphenyl)xanthin-9-yl, or 2-naphthylmethyl;

[0075] The isomers include: 6'-cyano modified locked nucleoside with the Z group in R configuration, the structural formula is Or the Z group is in the S-configuration 6'-cyano modified locked nucleoside, the structural formula is

[0076] The 6'-cyano modified locked nucleoside provided by the present invention can improve the nuclease tolerance of the nucleic acid polymer prepared using the 6'-cyano modified locked nucleoside as a raw material and reduce the interaction between the nucleic acid polymer and intracellular proteins.

[0077] In a second aspect, the present invention provides a nucleotide comprising a 3'-active phosphorus group derivative of the above-mentioned 6'-cyano modified locked nucleoside;

[0078] The active phosphorus group is selected from the group consisting of phosphoramidites, derivatives of phosphoramidites, H-phosphates, derivatives of H-phosphates, phosphotriesters, and derivatives of phosphotriesters.

[0079] The nucleotides provided by the present invention can improve the nuclease tolerance of nucleic acid polymers prepared using the nucleotides as monomers and reduce the interaction between the nucleic acid polymers and intracellular proteins.

[0080] In some embodiments, the nucleotide is selected from a compound having a structure as shown in Formula 2, a salt thereof, or an isomer thereof:

[0081] The isomers include: nucleotides with the Z group in the R configuration, the structural formula is Or the nucleotide with Z group in S configuration has the structural formula

[0082] In a third aspect, the present invention provides the use of the above-mentioned nucleotides in reducing the interaction between nucleic acid polymers and intracellular proteins.

[0083] The inventors have found through research that the nucleic acid polymers prepared using the nucleotides provided by the present invention have little interaction with intracellular proteins, which helps to reduce the in vivo toxicity of the nucleic acid polymers.

[0084] In a fourth aspect, the present invention provides a nucleic acid polymer having a monomer having a structure as shown in Formula 3:

[0085] In formula 3, Bx is selected from substituted or unsubstituted: adenine, guanine, thymine, cytosine, uracil or their respective salts;

[0086] Z is a cyano group;

[0087] W3 and W4 are each independently H, a hydroxyl protecting group, or an internucleoside linking group that connects the monomer to the rest of the nucleic acid polymer; and at least one of W3 and W4 is an internucleoside linking group that connects the monomer to the rest of the nucleic acid polymer;

[0088] The hydroxy protecting group is selected from but not limited to: acetyl, tert-butyl, tert-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, di(2-acetoxyethoxy)methyl, 2-trimethylsilylethyl, trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tritylsilyl alkyl, [(triisopropylsilyl)oxy]methyl, benzoylformate, chloroacetyl, trichloroacetyl, trifluoroacetyl, pivaloyl, benzoyl, p-phenylbenzoyl, 9-fluorenylmethyl carbonate, methanesulfonate, p-toluenesulfonate, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, 1(2-fluorophenyl)-4-methoxypiperidin-4-yl, 9-phenylxanthin-9-yl, 9-(p-methoxyphenyl)xanthin-9-yl, or 2-naphthylmethyl.

[0089] The nucleic acid polymer provided by the present invention has better nuclease tolerance than unmodified or other modified nucleic acid polymers. The nucleic acid polymer can reduce the interaction with intracellular proteins, reduce the impact on the subcellular distribution of intracellular proteins, and reduce cell apoptosis.

[0090] In some embodiments, the monomers include: monomers in which the Z group is in R configuration, with the structural formula Or the monomer with Z group in S configuration has the structural formula

[0091] In some embodiments, the nucleic acid polymer is ribonucleic acid, deoxyribonucleic acid, or a copolymer of ribonucleotides and deoxyribonucleotides.

[0092] In a fifth aspect, the present invention provides the use of the above-mentioned nucleic acid polymer in the preparation of a nucleic acid diagnostic agent or a nucleic acid therapeutic agent.

[0093] The nucleic acid polymer provided by the present invention has better nuclease tolerance than unmodified or other modified nucleic acid polymers, has low interaction with intracellular proteins, low induction of cell apoptosis, and small toxic side effects, and can be used as a nucleic acid diagnostic agent or nucleic acid therapeutic agent.

[0094] In a sixth aspect, the present invention provides a method for synthesizing a C6'-cyano modified nucleoside of R configuration or S configuration, wherein the C6'-cyano modified nucleoside of R configuration is The synthesis method comprises: Isomerization of terminal olefins to obtain Then, a dihydroxylation reaction was performed to obtain Then, aldehyde compounds are obtained through oxidative cleavage reaction. Finally The aldehyde group of the nucleoside was converted into a cyano group to obtain a C6'-position cyano-modified nucleoside with R configuration.

[0095] S-configuration C6'-position cyano-modified nucleoside The synthesis method comprises: Isomerization of terminal olefins to obtain Then, a dihydroxylation reaction was performed to obtain Then, aldehyde compounds are obtained through oxidative cleavage reaction. Finally The aldehyde group of the nucleoside was converted into a cyano group to synthesize an S-configuration C6' cyano-modified nucleoside.

[0096] wherein Bx is selected from substituted or unsubstituted adenine, guanine, thymine, cytosine, uracil or their respective salts.

[0097] The present invention does not impose any specific limitations on the reaction methods for terminal olefin isomerization, dihydroxylation, oxidative cleavage, and conversion of aldehyde groups to cyano groups; methods familiar to those skilled in the art may be employed. The R- or S-configured C6'-cyano-modified nucleosides synthesized in the present invention can be used as starting materials for the synthesis of four R- or S-configured cyano-modified locked nucleic acids.

[0098] It should be noted that the intermediate product aldehyde compound of the above reaction can be converted into other groups, including alkanes, alcohols, carboxylic acids, alkynyls, alkenyls and amines, through conventional chemical methods, thereby achieving diversified C6'-modified locked nucleic acids.

[0099] In some embodiments, the The synthesis method comprises: The mesylation reaction, debonding reaction and acetylation reaction were carried out in sequence to obtain Then, glycosylation reaction and nucleophilic substitution reaction were performed to synthesize the R configuration

[0100] described The synthesis method comprises: The mesylation reaction, debonding reaction and acetylation reaction were carried out in sequence to obtain Then glycosylation reaction and nucleophilic substitution reaction are carried out to synthesize the S configuration

[0101] The glycosidation reaction is as follows: under the condition of an activator, The method comprises reacting with thymine, N6-benzoyl adenine or 6-chloroguanine at 50-100° C.; wherein the activating agent comprises BSA and TMSOTf, and the reaction medium comprises acetonitrile, 1,2-dichloroethane or toluene.

[0102] The above-mentioned synthesis method provided by the present invention is stable and practical. There is no specific limitation on the mesylation reaction, debonding and acetylation reaction and nucleophilic substitution reaction, and reaction methods well known to those skilled in the art can be used.

[0103] In some embodiments, the S configuration The synthesis method comprises: 5-O-(tert-butyldiphenylsilyl)-4-C-hydroxymethyl-1,2-O-isopropylidene-3-O-(2-naphthylmethyl)-α-D-ribofuranose The primary alcohol is oxidized to an aldehyde group, and then the aldehyde group undergoes an allylation reaction to obtain the S configuration.

[0104] Preferably, the R configuration The synthesis method comprises: The secondary alcohol is oxidized to a ketone, and then the ketone is reduced to a secondary alcohol to obtain the R configuration.

[0105] In the process of reducing ketone to secondary alcohol, the reducing agent used includes metal hydride compounds such as lithium aluminum hydride, lithium borohydride, lithium chloride or sodium borohydride, the reaction medium includes solvents such as dichloromethane, tetrahydrofuran, methanol or ethanol, and the reaction temperature is between -78°C and 0°C.

[0106] Preferably, the reaction of reducing ketone to secondary alcohol is: using sodium borohydride and lithium chloride as reducing agents, tetrahydrofuran and methanol as reaction medium, and reacting at -40-0°C.

[0107] In some preferred embodiments, the catalyst for the isomerization of terminal olefins includes a transition metal catalyst such as a ruthenium catalyst, a palladium catalyst, a rhodium catalyst or an iridium catalyst, preferably tris(triphenylphosphine)carbonylruthenium(II) hydrochloride;

[0108] The reaction medium for the terminal olefin isomerization comprises methanol, ethanol, n-butanol or toluene, preferably ethanol;

[0109] The reaction temperature of the terminal olefin isomerization is 60-100°C, preferably 60-80°C;

[0110] The reaction time of the terminal olefin isomerization is 12-72 hours.

[0111] The inventors have found that terminal olefin isomerization can be stably achieved by using 2.5-5 mol% tris(triphenylphosphine)carbonylruthenium(II) hydrochloride as a catalyst and ethanol as a reaction solvent without the need for anhydrous and oxygen-free operation.

[0112] In a seventh aspect, the present invention provides a method for synthesizing a C6'-position cyano-locked nucleic acid T phosphoramidite monomer of R configuration or S configuration. The preparation method of the C6'-position cyano-locked nucleic acid T phosphoramidite monomer of R configuration comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the R configuration.

[0113] The preparation method of the S-configuration C6'-position cyano-locked nucleic acid T phosphoramidite monomer comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the S configuration.

[0114] The synthetic method is stable and efficient, and can be universally used for the synthesis of R-configuration or S-configuration C6'-position cyano-modified T phosphoramidite monomers.

[0115] In an eighth aspect, the present invention provides a method for synthesizing an R-configuration or S-configuration C6'-position cyano-locked nucleic acid A phosphoramidite monomer, wherein the R-configuration C6'-position cyano-locked nucleic acid A phosphoramidite monomer comprises: The bases are protected to obtain Then the 3'-hydroxyl and 5'-hydroxyl groups are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the R configuration.

[0116] The S-configuration C6'-position cyano-locked nucleic acid A phosphoramidite monomer includes: The bases are protected to obtain Then the 3'-hydroxyl and 5'-hydroxyl groups are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the S configuration.

[0117] The synthetic method is stable and efficient, and can be universally used for the synthesis of R-configuration or S-configuration C6'-position cyano-locked nucleic acid A phosphoramidite monomers.

[0118] In the ninth aspect, the present invention provides a method for synthesizing an R-configuration or S-configuration C6'-position cyano-locked nucleic acid G phosphoramidite monomer, and the preparation method of the R-configuration C6'-position cyano-locked nucleic acid G phosphoramidite monomer comprises: Demethylation of the methoxy group yields Then base protection is performed to obtain Then the 3'-hydroxyl and 5'-hydroxyl groups are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr and the 3'-hydroxyl group was phosphoramiditized to obtain R-configuration 8.

[0119] The preparation method of the S-configuration C6'-position cyano-locked nucleic acid G phosphoramidite monomer comprises: Demethylation of the methoxy group yields Then base protection is performed to obtain Then the 3'-hydroxyl and 5'-hydroxyl groups are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramiditized to obtain the S configuration.

[0120] The synthetic method is stable and efficient, and can be universally used for the synthesis of R-configuration or S-configuration C6'-position cyano-locked nucleic acid G phosphoramidite monomers.

[0121] In a tenth aspect, the present invention provides a method for synthesizing an R-configuration or S-configuration C6'-position cyano-locked nucleic acid C phosphoramidite monomer, and the preparation method of the R-configuration C6'-position cyano-locked nucleic acid C phosphoramidite monomer comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain Then the 5'-hydroxyl group was protected by DMTr to obtain The 3'-hydroxyl group is then silanized and the carbonyl group is converted into an amino group to obtain Then base protection is performed and the 3'-hydroxyl group is deprotected to obtain Finally, the 3'-hydroxyl group was phosphoramidated to obtain the R configuration.

[0122] The preparation method of the S-configuration C6'-position cyano-locked nucleic acid C phosphoramidite monomer comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain Then the 5'-hydroxyl group was protected by DMTr to obtain The 3'-hydroxyl group is then silanized and the carbonyl group is converted into an amino group to obtain Then base protection is performed and the 3'-hydroxyl group is deprotected to obtain Finally, the 3'-hydroxyl group was phosphoramiditized to obtain the S configuration.

[0123] The synthetic method is stable and efficient, and can be universally used for the synthesis of C6'-position cyano-locked nucleic acid C phosphoramidite monomers with R or S configurations.

[0124] In an eleventh aspect, the present invention provides a method for synthesizing a nucleic acid polymer, wherein monomers are polymerized to prepare a nucleic acid polymer;

[0125] The monomer includes the 6'-cyano modified locked nucleoside or the nucleotide.

[0126] In some preferred embodiments, the polymerization reaction includes: ① Chemical synthesis. Nucleic acids are synthesized entirely using organic chemical methods, including the phosphodiester method, the phosphotriester method, the phosphite triester method, and solid-phase synthesis. ② Enzymatic synthesis. Nucleic acid monomers or small chemically synthesized fragments can be linked into larger fragments through enzymatic reactions.

[0127] The present invention is further described below by way of specific examples. However, it should be understood that these examples are merely provided for more detailed description and are not to be construed as limiting the present invention in any form.

[0128] Example 1: Stereoselective Synthesis of Cyano-Locked Nucleic Acids

[0129] Part I: Synthesis of R-6'-CN-LNA

[0130] Synthesis of R-6'-allyl-LNA

[0131] The reaction conditions are as follows: (a) (1) 2-iodoacylbenzoic acid, acetonitrile, reflux, 5 h; (2) allyltrimethylsilane, boron trifluoride etherate, dichloromethane, -40 ° C, 4 h; (b) methylsulfonyl chloride, DMAP, pyridine, room temperature, 16 h; (c) (1) FeCl3·6H2O, dichloromethane, 0 ° C to room temperature, 9 h; (2) Ac2O, DMAP, pyridine, dichloromethane, room temperature, 2 h.

[0132] 2

[0133] Compound 1 (100.0 g, 0.167 mol) was dissolved in 500 mL of acetonitrile, and 2-iodoacylbenzoic acid (56 g, 0.20 mol) was added. The temperature was raised to reflux for 5 h. The reaction was complete after monitoring by TLC (petroleum ether / ethyl acetate = 5 / 1). The reaction was stopped, and the mixture was cooled to room temperature and filtered through celite. The filter cake was washed twice with acetonitrile, the solvent was evaporated, and vacuum dried to obtain 101 g of a light yellow liquid, which was directly used for the next step without purification.

[0134] The above-mentioned aldehyde compound was dissolved in 500 mL of dichloromethane, cooled to -40°C, and a solution of boron trifluoride in ether (22 mL, 0.217 mol) was added, and the reaction was stirred for 5 minutes. Allyltrimethylsilane (42.7 mL, 0.217 mol) was then added dropwise, and the temperature was maintained and stirred for 4 hours. The reaction was monitored by TLC (petroleum ether / ethyl acetate = 5 / 1) to confirm the completion of the reaction. The reaction solution was quickly poured into 1 L of saturated sodium bicarbonate aqueous solution for quenching; the mixture was extracted with dichloromethane, washed with saturated brine, dried over anhydrous NaSO4, filtered, and concentrated under reduced pressure to obtain 107 g of a light yellow viscous product 2, with a yield of 100%. No purification was required and the product could be directly processed into the next step. 1 H NMR(CDCl3,400MHz)δ7.86-7.78(m,4H),7.60-7.57(m,2H),7.53-7.46(m,5H),7.41-7.27(m,6H),5.87-5.80(m,2H),5.05-4.97(m, 3H),4.76(t,J=5.2Hz,1H),4.70-4.66(m,2H),4.47(dd,J=10.7,1.7Hz,1H),3.96(d,J=11.2Hz,1H),3.80(d,J=11.2Hz,1H),3.44(br s,1H),2.54-2.49(m,1H),1.93-1.85(m,1H),1.63(s,3H),1.39(s,3H),0.90(s,9H); 13C NMR(CDCl3,100MHz)δ136.41,135.58,135.50,134.29,133.30,133.22,133. 13,132.99,129.76,129.62,128.76,127.99,127.78,127.75,127.70,127.31 ,126.38,126.32,125.71,116.26,113.78,104.70,88.22,79.18,78.11,73.0 9,72.56,62.46,34.65,27.09,26.73,26.54,19.15; ESI-MS(m / z)637.37[MH] - .

[0135] 3

[0136] Compound 2 (100.0 g, 0.157 mol) and DMAP (1.9 g, 15.7 mmol) were dissolved in 500 mL of pyridine at room temperature. Methanesulfonyl chloride (18 mL, 0.235 mol) was added dropwise and allowed to react at room temperature for 16 h. The reaction was complete as monitored by TLC (petroleum ether / ethyl acetate = 5 / 1). 100 mL of methanol was added to the reaction solution and stirred for 10 min to quench the reaction. The reaction solution was then concentrated under reduced pressure to remove excess pyridine, diluted with ethyl acetate, washed sequentially with water, 1N HCl solution, and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash column chromatography (gradient elution: petroleum ether / ethyl acetate = 0-25%) to obtain 108.0 g of colorless viscous product 3, with a yield of 96%.

[0137] 1 H NMR(DMSO-d6,400MHz)δ7.95-7.85(m,4H),7.56-7.36(m,13H),5.80-5.69(m,2 H),5.40(dd,J=7.6,3.2Hz,1H),5.03-4.93(m,4H),4.69(d,J=12.4Hz,1H),4.4 0(d,J=5.3Hz,1H),3.75(d,J=11.0Hz,1H),3.60(d,J=11.0Hz,1H),2.97(s,3H) ,2.85-2.81(m,1H),2.58-2.52(m,1H),1.53(s,1H),1.33(s,1H),0.78(s,9H); 13C NMR(CDCl3,100MHz)δ135.59,135.52,135.29,134.59,133.25,133.19,132.8 8,132.84,130.39,130.36,128.59,128.34,128.29,128.24,128.09,127.33,1 26.70,126.55,126.34,118.60,113.27,105.00,87.47,81.43,78.15,76.97, 71.93,64.30,36.19,26.83,26.57,26.33,19.04; ESI-MS(m / z)734.39[M+NH4] + ,739.34[M+Na] + .

[0138] 4

[0139] A 600 mL dichloromethane solution of compound 3 (108 g, 0.15 mol) was cooled to 0°C, and ferric chloride hexahydrate (16.3 g, 0.06 mol) was added thereto. The mixture was reacted at room temperature for 9 h. The reaction was complete after monitoring by TLC (petroleum ether / ethyl acetate = 4 / 1). The reaction solution was poured into 1.5 L of water and extracted with dichloromethane. The organic layer was washed with water, saturated sodium bicarbonate solution, and saturated brine in sequence, dried over anhydrous magnesium sulfate, filtered, concentrated under reduced pressure, and dried in vacuo. The resulting viscous material was dissolved in 500 mL of dichloromethane, and pyridine (72 mL, 0.9 mol) and DMAP (2.75 g, 22.5 mol) were added in sequence. Acetic anhydride (85 mL, 0.9 mol) was then added dropwise. The mixture was reacted at room temperature for 2 h. The reaction was complete after monitoring by TLC (petroleum ether / ethyl acetate = 4 / 1). The reaction mixture was poured into 2 L of water and extracted with dichloromethane. The organic layer was washed sequentially with water, 1 N HCl solution, saturated sodium bicarbonate solution, and saturated brine, dried over anhydrous magnesium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: petroleum ether / ethyl acetate = 0-60%) to obtain 68 g of a mixture of diacetyl compound 4 as a colorless viscous product, with a yield of 60%. ESI-MS (m / z) 778.39 [M+NH4] + ,783.44[M+Na] + .

[0140] Reaction conditions were as follows: (a) thymine, N,O-bis(trimethylsilyl)acetamide (BSA), TMSOTf, acetonitrile, 80°C, 3 h; (b) K2CO3, methanol, room temperature, 16 h; (c) N6-benzoyl adenine, BSA, TMSOTf, toluene, 100°C, 3 h; (d) 6-chloroguanine, BSA, TMSOTf, toluene, 100°C, 3 h.

[0141] 5

[0142] To a suspension of thymine (7.6 g, 60 mmol) in 50 mL of acetonitrile, BSA (29 mL, 120 mmol) was added and stirred at room temperature for 20 min until the thymine dissolved. After the system became clear, a solution of diacetylated sugar 4 (23 g, 30 mmol) in 200 mL of acetonitrile was added, followed by rapid dropwise addition of TMSOTf (8.3 mL, 45 mmol). After the addition was complete, the temperature was raised to 80 ° C and the reaction was stirred for 3 h. The reaction was monitored by TLC (petroleum ether / ethyl acetate = 5 / 1) to determine completion. Heating was stopped, and after the reaction solution cooled to room temperature, the reaction solution was poured into ethyl acetate, to which was added a half-saturated NaHCO solution (400 mL) and stirred for 20 min. The insoluble solid was filtered off with celite, the organic layer was separated, and then washed with water and saturated brine in sequence, dried over anhydrous NaSO, filtered, concentrated, and dried in vacuo. The resulting residue was dissolved in 250 mL of methanol, to which KCO (12.4 g, 90 mmol) was added, and the reaction was allowed to react at room temperature for 16 h. TLC detection showed that the reaction was complete (dichloromethane / ethyl acetate = 10 / 3). After the reaction solution was concentrated, the residue was extracted with ethyl acetate, washed with water and saturated brine in sequence, dried over anhydrous NaSO, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-40%) to obtain 8 g of locked nucleic acid derivative 5 as a white foamy solid in a yield of 39%. 1 H NMR(CDCl3,400MHz)δ8.72(br s,1H),7.82-7.74(m,3H),7.72(s,1H),7.68-7.63(m,4H),7.59(s,1H),7.75-7.28(m ,9H),5.80-5.69(m,1H),5.66(s,1H),5.11-5.00(m,2H),4.87(d,J=11.4Hz,1H),4.7 4-4.71(d,J=11.4Hz,1H),4.57(s,1H),4.24-4.20(m,2H),4.03(d,J=12.0Hz,1H),3. 91(d,J=12.0Hz,1H),2.49-2.42(m,1H),2.26-2.22(m,1H),1.56(s,3H),1.09(s,9H); 13C NMR(CDCl3,100MHz)δ163.60,149.72,135.44,135.27,134.23,134.16,133.6 4,133.11,132.70,132.25,130.10,130.06,128.42,127.98,127.85,127.73, 126.88,126.39,126.25,125.74,117.88,110.42,89.20,86.82,79.97,77.05 ,76,47,72.53,58.80,33.76,26.97,19.44,12.04; ESI-MS(m / z)689.41[M+H] + ,711.38[M+Na] + .

[0143] 6

[0144] To a 50 mL toluene suspension of N6-benzoyl adenine (14 g, 60 mmol) was added BSA (29 mL, 120 mmol), and the mixture was heated to 60°C and reacted until the N6-benzoyl adenine was dissolved and the system became clear. The reaction solution was then cooled to room temperature, and a 170 mL toluene solution of diacetylated sugar 4 (23 g, 30 mmol) was added. TMSOTf (8.3 mL, 45 mmol) was then quickly added dropwise. After the addition was complete, the temperature was raised to 100°C and the reaction was stirred for 3 h. The reaction was monitored by TLC (petroleum ether / ethyl acetate = 5 / 1) for completion. Heating was stopped, and after the reaction solution cooled to room temperature, the reaction solution was poured into ethyl acetate, to which was added a half-saturated NaHCO solution (400 mL) and stirred for 20 min. The insoluble solid was filtered off with celite, the organic layer was separated, and then washed with water and saturated brine in sequence, dried over anhydrous NaSO, filtered, concentrated, and dried in vacuo. The resulting residue was dissolved in 250 mL of methanol, to which KCO (20.7 g, 150 mmol) was added, and the reaction was allowed to react at room temperature for 16 h. TLC detection showed that the reaction was complete (dichloromethane / ethyl acetate = 10 / 3). After the reaction solution was concentrated, the residue was extracted with ethyl acetate, washed with water and saturated brine in sequence, dried over anhydrous NaSO, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-100%) to obtain 7.4 g of locked nucleic acid derivative 6 as a white powdery solid with a yield of 35%. 1H NMR(CDCl3,400MHz)δ8.28(s,1H),8.15(s,1H),7.80-7.64(m,8H),7.47-7.28(m,9H),6.06(s,1H),5.93-5.91(m,2H),5.82-5.75(m,1H),5.13(d,J=17.1Hz,1H),5.04(d,J=10.2Hz,1H),4.81-4.72(m,3H),4.52(s, 1H),4.32-4.29(m,1H),4.02(d,J=12.0Hz,1H),3.92(d,J=12.0Hz,1H),2.55-2.49(m,1H),2.34-2.27(m,1H),1.07(s,9H); 13 C NMR(CDCl3,100MHz)δ155.46,153.16,148.82,135.59,135.49,130.02,129.99,128.36,127.96,127.92,127.83,127.70,126.78,126.29,120.09,117.83,88.57,86.16,80.45,78.74,76.64,72.75,58.82,33.90,26.79,19.22;ESI-MS(m / z)698.36[M+H] + ,720.35[M+Na] + .

[0145] 7

[0146] To a suspension of 6-chloroguanine (10.2 g, 60 mmol) in 50 mL of toluene was added BSA (29 mL, 120 mmol), and the mixture was heated to 60°C and reacted until 6-chloroguanine dissolved and the system became clear. The reaction solution was then cooled to room temperature, and a 170 mL toluene solution of diacetylated sugar 4 (23 g, 30 mmol) was added. TMSOTf (8.3 mL, 45 mmol) was then added dropwise rapidly. After the addition was complete, the mixture was heated to 100°C and stirred for 3 h. The reaction was monitored to be complete by TLC (petroleum ether / ethyl acetate = 5 / 1). Heating was stopped, and after the reaction solution cooled to room temperature, the reaction solution was poured into ethyl acetate, to which was added a half-saturated NaHCO solution (400 mL) and stirred for 20 min. The insoluble solid was filtered off with celite, the organic layer was separated, and then washed with water and saturated brine in sequence, dried over anhydrous NaSO, filtered, concentrated, and dried in vacuo. The resulting residue was dissolved in 250 mL of methanol, to which KCO (20.7 g, 150 mmol) was added, and the reaction was allowed to react at room temperature for 16 h. TLC detection showed that the reaction was complete (dichloromethane / ethyl acetate = 10 / 3). After the reaction solution was concentrated, the residue was extracted with ethyl acetate, washed with water and saturated brine in sequence, dried over anhydrous NaSO, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-30%) to obtain 12.2 g of locked nucleic acid derivative 7 as a white foamy solid in a yield of 56%. 1 H NMR(CDCl3,400MHz)δ7.98(s,1H),7.82-7.67(m,8H),7.49-7.36(m,7H),7. 31-7.27(m,2H),5.92(s,1H),5.84-5.74(m,1H),5.14-5.01(m,2H),4.95(br s,2H),4.79(dd,J=17.7,11.5Hz,2H),4.58(s,1H),4.53(s,1H),4.31(dd,J=8.6,5.0Hz,1H),4.08(s,3 H),4.00(d,J=12.0Hz,1H),3.90(d,J=12.0Hz,1H),2.56-2.48(m,1H),2.34-2.27(m,1H),1.07(s,9H); 13C NMR(CDCl3,100MHz)δ161.49,159.36,142.45,136.44,135.62,134.47,133 .94,133.14,133.08,132.53,132.47,129.97,128.34,127.94,127.90,127. 69,126.67,126.25,126.12,125.65,117.75,116.09,88.31,85.93,80.46, 78.93,72.80,58.86,53.91,33.93,26.78,19.17; ESI-MS(m / z)728.39[M+H] + .

[0147] Synthesis of R-6'-CN-LNA

[0148] The reaction conditions are as follows: (a)(1) tris(triphenylphosphine)carbonylruthenium(II) hydrochloride (Wilkinson's catalyst), EtOH, 80°C, 48 h; (b) potassium osmate dihydrate, 50% NMO, t-BuOH, H2O, 60°C, 8 h; (c) NaIO4, EtOH-THF (2 / 1 v / v), H2O, room temperature, 12 h; (d) NH4OH, I2, room temperature, 24 h.

[0149] 8

[0150] To a solution of allyl nucleoside derivative 5 (5.0 g, 7.26 mmol) in 50 mL of anhydrous ethanol was added tris(triphenylphosphine)carbonylruthenium(II) chloride (345 mg, 0.36 mmol, 5% mol), and the mixture was heated to 80°C for 48 h. The reaction solution was directly concentrated, and the residue was dissolved in 40 mL of tetrahydrofuran. 5 mL of tert-butanol and 5 mL of water, potassium osmate dihydrate (26.7 mg, 72.6 μmol, 1% mol), and 50% N-methylmorpholine-N-oxide (2.3 mL, 10.9 mmol) were added in sequence. The mixture was heated to 60°C for 8 h. The reaction was complete when detected by TLC (dichloromethane / methanol = 10 / 1). After quenching the reaction with saturated sodium sulfite solution, the mixture was extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate containing 5% methanol / dichloromethane = 0-80%) to obtain 5 g of a mixed dihydroxylated isomeric product.

[0151] The above-mentioned bishydroxylation product was dissolved in 60 mL of ethanol-tetrahydrofuran solution, and a 10 mL aqueous solution of NaIO4 (2.33 g, 10.9 mmol) was added dropwise thereto, and the mixture was stirred at room temperature for 12 h. After filtering out the insoluble solid, 25% aqueous ammonia (5.5 mL, 72.6 mmol) was added to the filtrate, followed by addition of I2 (1.84 g, 7.26 mmol) in portions, and the mixture was allowed to react at room temperature for 24 h. The reaction was quenched with saturated sodium sulfite solution, extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate containing 5% methanol / dichloromethane = 0-60%) to obtain 3.3 g of the slightly gray foamy solid product 8 in a yield of 48%. 1 H NMR(CDCl3,400MHz)δ8.99,7.85-7.76(m,3H),7.68-7.64(m,5H),7.52-7.42(m,5H),7.38-7.33(m,5H),5.84(s,1H),4.87(s,1H),4.83( s,1H),4.82(d,J=6.6Hz,1H),4.71(d,J=6.6Hz,1H),4.24(s,1H),4.17(d,J=6.9Hz,1H),4.01(d,J=6.9Hz,1H),1.63(s,3H),1.10(s,9H); 13 C NMR(CDCl3,100MHz)δ163.50,149.61,135.53,135.32,133.63,133.25,133.2 1,133.05,132.10,131.80,130.36,130.32,128.68,128.15,128.10,127.86, 127.80,127.15,126.63,126.56,125.58,115.47,111.18,89.24,87.30,78.0 6,76.26,72.81,70.55,58.15,26.86,19.43,12.24; ESI-MS(m / z)674.28[M+H] + ,796.25[M+Na] + .

[0152] 9

[0153] To a solution of allyl nucleoside derivative 6 (7.0 g, 10 mmol) in 70 mL of anhydrous ethanol was added tris(triphenylphosphine)carbonylruthenium(II) chloride (475 mg, 0.5 mmol, 5% mol), and the mixture was heated to 80°C for 48 h. The reaction solution was directly concentrated, and the residue was dissolved in 50 mL of tetrahydrofuran. 10 mL of tert-butanol and 10 mL of water, potassium osmate dihydrate (37 mg, 0.1 mmol, 1% mol), and 50% N-methylmorpholine-N-oxide (3.13 mL, 15 mmol) were added in sequence. The mixture was heated to 60°C for 8 h. The reaction was complete when detected by TLC (dichloromethane / methanol = 10 / 1). After quenching the reaction with saturated sodium sulfite solution, the mixture was extracted with ethyl acetate, washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-10%) to obtain 7.5 g of a mixed dihydroxylated isomeric product.

[0154] The above-mentioned bishydroxylation product was dissolved in 60 mL of ethanol-tetrahydrofuran solution, and a 15 mL aqueous solution of NaIO4 (3.2 g, 10.9 mmol) was added dropwise thereto, and the mixture was stirred at room temperature for 12 h. After the insoluble solid was filtered off, 25% ammoniacal liquor (7.6 mL, 100 mmol) was added to the filtrate, and then I2 (2.54 g, 10 mmol) was added portionwise, and the reaction was allowed to proceed at room temperature for 24 h. The reaction was quenched with saturated sodium sulfite solution, extracted with ethyl acetate, washed with water, washed with saturated common salt water, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash column chromatography (eluent ethyl acetate / dichloromethane = 0-40%) to obtain 1.2 g of slightly yellowish foamy solid product 9 in a yield of 26%. 1 H NMR(DMSO-d6,400MHz)δ10.71(s,1H),7.92-7.81(m,5H),7.66-7.61(m,4H),7.54-7.36(m,9H),6.66(br s,2H),6.04(s,1H),5.30(s,1H),5.13(s,1H),4.92(d,J=12.0Hz,1H),4.84(d,J=12 .0Hz,1H),4.79(s,1H),4.21(d,J=12.2Hz,1H),4.00(d,J=12.2Hz,1H),0.94(s,9H); 13C NMR(DMSO-d6,100MHz)δ157.14,154.49,151.10,135.62,135.28,134.48,132.15,130.53,128.44,128.15,128.07,128.76,126 .64,126.57,126.17,117.74,116.98,88.23,84.86,78.84,78.44,71.98,71.22,59.76,26.77,19.19; ESI-MS(m / z)683.30[M+H] + ,705.27[M+Na] + .

[0155] 10

[0156] To a solution of allyl nucleoside derivative 7 (11.0 g, 15.1 mmol) in 120 mL of anhydrous ethanol was added tris(triphenylphosphine)carbonylruthenium(II) chloride (718 mg, 0.76 mmol, 5% mol), and the mixture was heated to 80°C for 48 h. The reaction solution was directly concentrated, and the residue was dissolved in 80 mL of tetrahydrofuran. 10 mL of tert-butanol and 10 mL of water, potassium osmate dihydrate (56 mg, 0.15 mmol, 1% mol), and 50% N-methylmorpholine-N-oxide (4.7 mL, 22.7 mmol) were added in sequence. The mixture was heated to 60°C for 8 h. The reaction was complete when detected by TLC (dichloromethane / methanol = 10 / 1). After quenching the reaction with saturated sodium sulfite solution, the mixture was extracted with ethyl acetate, washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-60%) to obtain 8 g of a mixed dihydroxylated isomeric product.

[0157] The above-mentioned bishydroxylation product was dissolved in 70 mL of ethanol-tetrahydrofuran solution, and a 15 mL aqueous solution of NaIO4 (3.4 g, 10.9 mmol) was added dropwise thereto, and the mixture was stirred at room temperature for 12 h. After filtering out the insoluble solid, 25% aqueous ammonia (7.9 mL, 105 mmol) was added to the filtrate, followed by addition of I2 (2.67 g, 10.5 mmol) in portions, and the mixture was allowed to react at room temperature for 24 h. The reaction was quenched with saturated sodium sulfite solution, extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-40%) to give 4 g of the slightly yellowish foamy solid product 10 in a 37% yield. 1H NMR(CDCl3,400MHz)δ7.82-7.76(m,3H),7.71-7.16(m,6H),7.51-7.30(m,9H),6.10(s,1H),4.95(s,1H),4.92(s,1H),4.77(br s,2H),4.73(d,J=2.7Hz,2H),4.50(s,1H),4.14(d,J=12.0Hz,1H),4.07(s,3H),4.02(d,J=12.0Hz,1H),1.10(s,9H); 13 C NMR(CDCl3,100MHz)δ161.60,159.29,152.25,136.27,135.67,135.54,133.6 0,133.16,133.05,132.09,132.07,130.16,128.60,128.03,127.97,127.86, 127.73,126.88,126.49,126.42,125.43,116.04,115.82,88.54,86.26,78.1 9,77.97,72.96,71.05,58.73,54.02,26.69,19.20; ESI-MS(m / z)713.40[M+H] +

[0158] Synthesis of R-6'-CN-LNA phosphoramidite monomer

[0159] Synthesis of R-6'-CN-LNA-T Phosphoramidite Monomer

[0160] The reaction conditions are as follows: (a) (1) DDQ, dichloromethane-H2O (20 / 1), room temperature, 24 h; (2) Et3N, Et3N·3HF, THF, room temperature, 9 h; (b) DMTrCl, pyridine, room temperature, 12 h; (c) 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite, 1H-tetrazole, room temperature, 5 h.

[0161] 11

[0162] At room temperature, DDQ (420 mg, 1.86 mmol) was added to a mixture of nucleoside derivative 8 (500 mg, 0.74 mmol) in 10.5 mL of dichloromethane-water (20:1). The mixture was allowed to react at room temperature for 24 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). The reaction solution was concentrated under reduced pressure, extracted with ethyl acetate, washed sequentially with saturated sodium sulfite solution, sodium bicarbonate solution, and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was dissolved in 10 mL of tetrahydrofuran, and triethylamine (260 μL, 1.86 mmol) and triethylamine trihydrofluoride (363 μL, 2.23 mmol) were added sequentially. The reaction was allowed to react at room temperature for 9 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). To the reaction solution was added 600 mg of solid sodium bicarbonate, and the mixture was stirred until no bubbles were generated. The reaction solution was concentrated under reduced pressure and directly purified by flash column (gradient elution: methanol / dichloromethane = 0-20%) to obtain 310 mg of colorless amorphous solid 11, with a yield of 46%. 1 H NMR (CD3OD, 400MHz) δ7.70(s,1H),5.69(s,1H),4.93(s,1H),4.46(s,1H),4.27(s,1H),3.96(s,2H),1.89(s,3H); 13 C NMR(CD3OD,100MHz)δ164.99,150.36,134.88,116.13,109.72,89.51,86.69,80.73,69.97,69.38,55.23,11.26; ESI-MS(m / z)296.13[M+H] + .

[0163] 12

[0164] To a solution of cyano-locked nucleoside derivative 11 (8.0 g, 27.1 mmol) in 50 mL of pyridine was added 4,4'-dimethoxytrityl chloride (13.8 g, 40.6 mmol). The mixture was stirred at room temperature for 12 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). The reaction was quenched with 50 mL of methanol and concentrated under reduced pressure. The residue was diluted with ethyl acetate, washed sequentially with water and saturated brine, dried over Na2SO4, concentrated, and purified by flash column chromatography (gradient elution: methanol / dichloromethane = 0-10%) to afford 13.53 g of 5'-O-DMTr-protected nucleoside 12 as a pale yellow powder in an 84% yield. 1H NMR (400MHz, DMSO-d6) δ11.48(s,1H),7.47-6.91(m,14H),6.27(d,J=4.0Hz,1H),5.63(s,1H),5.01(s,1H),4.52( s,1H),3.42(d,J=4.4Hz,1H),3.74(s,6H),3.65(d,J=11.2Hz,1H),3.36(d,J=11.2Hz,1H),1.60(d,J=0.8Hz,3H); 13 C NMR (100MHz, DMSO-d6) δ163.81,158.27,149.91,144.50,135.07,134.84,134.00,129.91,129.84,128.00,127.71,126. 94,117.41,113.34,109.01,87.99,86.38,86.35,80.37,70.52,70.33,58.47,55.09,12.35; ESI-MS(m / z)620.20[M+Na] + .

[0165] 13

[0166] To a solution of nucleoside 12 (4.0 g, 6.7 mmol) and 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (3.0 g, 10.0 mmol) in 40 mL of dichloromethane was added 1H-tetrazole (376 mg, 5.36 mmol). The mixture was allowed to react at room temperature for 5 h. The reaction was complete as determined by TLC (ethyl acetate / dichloromethane = 5 / 1). Saturated NaHCO3 solution was added to the reaction solution, which was extracted with dichloromethane, washed with saturated brine, dried over MgSO4, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-20%) to afford 4.4 g of phosphoramidite 13 as a white foamy solid in an 82% yield. 31 PNMR(152MHz,DMSO-d6)δ148.80,148.75; ESI-MS(m / z)798.32[M+H] + .

[0167] Synthesis of R-6'-CN-LNA-A Phosphoramidite Monomer

[0168] The reaction conditions are as follows: (a) BzCl, pyridine, room temperature, 6 h; (b) (1) DDQ, dichloromethane-H2O (20 / 1), room temperature, 24 h; (2) Et3N, Et3N·3HF, THF, room temperature, 12 h; (b) DMTrCl, pyridine, room temperature, 12 h; (c) 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite, 1H-tetrazole, room temperature, 8 h.

[0169] 14

[0170] Benzoyl chloride (1.52 mL, 13.2 mmol) was added dropwise to a solution of nucleoside 9 (3.0 g, 4.4 mmol) in 20 mL of pyridine at room temperature. The reaction was allowed to react for 6 h at room temperature. The reaction was complete when determined by TLC (dichloromethane / ethyl acetate = 10 / 1). 15% NaOH solution was added dropwise to the reaction solution to adjust the pH to 8-9, and the reaction was allowed to react for 4 h at room temperature. The reaction solution was diluted with ethyl acetate, washed sequentially with water, 1N HCl solution, and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-60%) to obtain 1.45 g of benzoyl-protected nucleoside 14 as a light yellow solid in a 42% yield. 1 H NMR (CDCl3, 400MHz) δ8.62 (s, 1H), 8.20 (s, 1H), 8.07 (d, J = 7.0Hz, 2H), 7.82-7.75 (m, 2H), 7.69-7.32 (m, 18H), 6.25 (s, 1H), 5.11(s,1H),4.98(s,1H),4.77(s,2H),4.51(d,J=5.8Hz,1H),4.16(d,J=12.5Hz,1H),4.04(d,J=12.5Hz,1H),1.07(s,9H); 13 C NMR(CDCl3,100MHz)δ164.60,152.64,150.42,149.70,140.19,135.55,133.53,133 .42,133.09,132.99,132.12,132.09,130.15,128.94,128.52,128.00,127.92,127. 91,127.85,127.69,126.80,126.38,126.28,125.42,123.29,114.42,90.04,86.43 ,78.19,77.54,72.97,70.17,59.42,29.70,26.70,19.26; ESI-MS(m / z)787.32[M+H] + .

[0171] 15

[0172] At room temperature, DDQ (1.03 g, 3.81 mmol) was added to a mixture of nucleoside derivative 14 (1.2 g, 1.52 mmol) in 21 mL of dichloromethane-water (20:1). The mixture was allowed to react at room temperature for 24 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). The reaction solution was concentrated under reduced pressure, extracted with ethyl acetate, washed sequentially with saturated sodium sulfite solution, sodium bicarbonate solution, and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was dissolved in 15 mL of tetrahydrofuran, and triethylamine (530 μL, 3.81 mmol) and triethylamine trihydrofluoride (743 μL, 4.56 mmol) were added sequentially. The reaction was allowed to react at room temperature for 12 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). 1.15 g of solid sodium bicarbonate was added to the reaction solution, and the mixture was stirred until no bubbles were generated. The reaction solution was concentrated under reduced pressure and directly purified by flash column (gradient elution: dichloromethane / methanol = 0-15%) to obtain 400 mg of cyano-locked nucleoside 15 with a yield of 64%. 1 H NMR (CD3OD, 400MHz) δ8.72(s,1H),8.55(s,1H),8.07(d,J=4.2Hz,2H),7.66(t,J=4.2Hz,1H ),7.57(t,J=4.2Hz,2H),6.30(s,1H),5.05(s,1H),4.88(s,1H),4.64(s,1H),4.02(s,2H); 13 C NMR(CD3OD,100MHz)δ166.76,152.06,151.09,149.81,141.56,132.46,132.57,128.38,12 8.06,123.91,116.25,89.47,86.11,80.84,70.77,70.43,55.86; ESI-MS(m / z)409.15[M+H] + .

[0173] 16

[0174] To a solution of cyano-locked nucleoside 15 (300 mg, 0.75 mmol) in 5 mL of pyridine was added 4,4'-dimethoxytrityl chloride (481 mg, 1.42 mmol) at room temperature and stirred at room temperature for 12 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). The reaction was quenched with 1 mL of methanol and concentrated under reduced pressure. The residue was diluted with ethyl acetate, washed sequentially with water and saturated brine, dried over Na2SO4, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate containing 5% methanol / dichloromethane = 0-45%) to afford 500 mg of 5'-O-DMTr-protected cyano-locked nucleoside 16 as a light yellow solid in a 94% yield. 1H NMR(DMSO-d6,400MHz)δ12.26(s,1H),8.79(s,1H),8.59(s,1H),8.06(d,J=8.4Hz,2H ),7.67(t,J=7.4Hz,1H),7.58(t,J=7.8Hz,2H),7.46(d,J=7.4Hz,1H),7.33-7.20(m,7 H),6.89(d,J=8.4Hz,4H),6.33(s,1H),6.30(d,J=4.3Hz,1H),5.12(s,1H),4.95(s,1H ),4.83(d,J=4.2Hz,1H),3.73(s,6H),3.68(d,J=11.2Hz,1H),3.40(d,J=11.2Hz,1H); 13 C NMR(DMSO-d6,100MHz)δ166.09,158.65,152.31,152.02,151.00,144.95,142.63,135.66,135.42,133.77,132.98,130.34,130.28,128.98, 128.97,128.33,128.96,127.26,126.02,118.26,113.71,88.34,86.8 3,85.69,80.94,72.59,71.24,60.23,55.51; ESI-MS(m / z)711.36[M+H] + .

[0175] 17

[0176] To a solution of nucleoside 16 (450 mg, 0.63 mmol) and 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (382 mg, 1.27 mmol) in 10 mL of dichloromethane was added 1H-tetrazole (35 mg, 0.51 mmol) at room temperature. The reaction was allowed to react for 8 h. TLC analysis indicated that the reaction was complete (dichloromethane / ethyl acetate = 5 / 2). The reaction solution was directly purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-40%) to afford 480 mg of phosphoramidite 17 as a slightly yellowish foamy solid in an 83% yield. 31 PNMR(152MHz,DMSO-d6)δ149.19,149.04; ESI-MS(m / z)909.38[MH] - .

[0177] Synthesis of R-6'-CN-LNA-G Phosphoramidite Monomer

[0178] The reaction conditions are as follows: (a) 2N HCl, THF-CH3OH (1 / 1), 60℃, 12h; (b) isobutyryl chloride, Et3N, DMAP, 1,4-dioxane, 100℃, 24h; (c) (1) DDQ, dichloromethane-H2O (20 / 1), room temperature, 24h; (2) Et3N, Et3N·3HF, THF, room temperature, 12h; (d) DMTrCl, pyridine, room temperature, 12h; (e) 2-CyanoethylN,N,N',N'-tetraisopropylphosphordiamidite, 1H-tetrazole, room temperature, 12h.

[0179] 18

[0180] To a 30 mL tetrahydrofuran-methanol solution (1 / 1 v / v) of cyano-locked nucleoside 10 (2.5 g, 3.5 mmol) was added 17.5 mL of 2N hydrochloric acid solution, and the mixture was heated to 60° C. for 12 h. A white solid precipitated, and the reaction was complete by TLC (dichloromethane / ethyl acetate = 2 / 1). The insoluble white solid was filtered out, and the filtrate was extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the filtrate was combined and purified by flash column chromatography (gradient elution: ethyl acetate containing 5% methanol / dichloromethane = 0-60%) to obtain 1.4 g of 6-demethylated nucleoside 18 as a white solid in a yield of 57%. 1 H NMR(DMSO-d6,400MHz)δ10.71(s,1H),7.92-7.81(m,5H),7.66(m,4H),7.54-7.49(m,2H),7.47-7.36(m,7H),6.66(br s,2H),6.04(s,1H),5.29(s,1H),5.13(s,1H),4.92(d,J=12.0Hz,1H),4.84(d,J=12 .0Hz,1H),4.78(s,1H),4.21(d,J=12.2Hz,1H),4.01(d,J=12.2Hz,1H),0.94(s,9H); 13C NMR(DMSO-d6,100MHz)δ157.13,154.49,151.10,135.62,135.60,135.29,134.48,133.17,133.01,132.46,132.46,130.52,128.44,128.15,128 .07,126.75,126.65,126.56,126.17,117.70,117.02,88.24,84.89,78. 86,78.48,72.02,71.23,59.76,26.80,19.20; ESI-MS(m / z)699.39[M+H] + ,721.48[M+Na] + .

[0181] 19

[0182] To a solution of guanosine 18 (1.2 g, 1.72 mmol) in 12 mL of 1,4-dioxane were added DMAP (105 mg, 0.86 mmol) and triethylamine (718 μL, 5.16 mmol), followed by isobutyryl chloride (550 μL, 5.16 mmol). The mixture was heated to 100°C and allowed to react for 24 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). Heating was discontinued, and the reaction solution was cooled to room temperature. 1 mL of methanol was added to quench the reaction, followed by extraction with ethyl acetate, washing with water and saturated brine, drying over anhydrous sodium sulfate, filtering, concentrating, and purification by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-80%) to afford 1.1 g of isobutyryl-protected guanosine 19 as a slightly yellow foamy solid in 83% yield. 1 H NMR(CDCl3,400MHz)δ12.00(s,1H),9.02(s,1H),7.78-7.74(m,3H),7.69-7.63 (m,5H),7.52(s,1H),7.47-7.28(m,9H),5.86(s,1H),4.87(s,1H),4.76(d,J=11 .6Hz,1H),4.66(d,J=11.6Hz,1H),4.47(s,1H),4.33(s,1H),4.13(d,J=12.0Hz, 1H), 4.02 (d, J = 12.0Hz, 1H), 2.70-2.66 (m, 1H), 1.29-1.24 (m, 6H), 1.08 (s, 9H); 13C NMR (CDCl3, 100MHz) δ178.83,155.24,147.84,146.82,135.64,135.49,135.11,133. 37,133.11,132.95,131.99,131.93,130.25,130.22,128.67,128.07,128.01,127.74 ,127.59,127.25,126.61,126.53,125.70,131.62,115.87,86.71,86.12,78.40,73. 33,71.03,58.74,36.40,26.71,19.78,19.21,18.99; ESI-MS(m / z)870.60[M+Et3N+H] - .

[0183] 20

[0184] At room temperature, DDQ (702 mg, 3.64 mmol) was added to a mixture of nucleoside derivative 19 (800 mg, 1.04 mmol) in 10.5 mL of dichloromethane-water (20:1). The mixture was allowed to react at room temperature for 24 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). The reaction solution was concentrated under reduced pressure, extracted with ethyl acetate, washed sequentially with saturated sodium sulfite solution, sodium bicarbonate solution, and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was dissolved in 10 mL of tetrahydrofuran, and triethylamine (363 μL, 2.60 mmol) and triethylamine trihydrofluoride (509 μL, 3.12 mmol) were added sequentially. The reaction was allowed to react at room temperature for 12 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). 786 mg of solid sodium bicarbonate was added to the reaction solution, and the mixture was stirred until no bubbles were generated. The reaction solution was concentrated under reduced pressure and directly purified by flash column (gradient elution: dichloromethane / methanol = 0-25%) to obtain 230 mg of cyano-locked nucleoside 20, with a yield of 57%. 1 H NMR (CD3OD, 400MHz) δ8.09(s,1H),6.08(s,1H),5.01(s,1H),4.73(s,1H),4.54(s,1H),3.99(s,2H),2.72-2.68(m,1H),1.23-1.21(m,6H); 13 C NMR(CD3OD,100MHz)δ180.35,148.67,148.20,136.57,120.03,116.22,89.37,85.62,8 0.91,70.56,70.35,55.80,46.48,35.58,17.92,17.90,7.84; ESI-MS(m / z)391.08[M+H]+ ,413.05[M+Na] + .

[0185] twenty one

[0186] To a solution of cyano-locked nucleoside 20 (150 mg, 0.384 mmol) in 5 mL of pyridine was added 4,4'-dimethoxytrityl chloride (260 mg, 0.77 mmol) at room temperature and stirred at room temperature for 12 h. The reaction was complete by TLC (dichloromethane / methanol = 5 / 1). The reaction was quenched with 2 mL of methanol and concentrated under reduced pressure. The residue was diluted with ethyl acetate, washed sequentially with water and saturated brine, dried over Na2SO4, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate containing 5% methanol / dichloromethane = 0-40%) to obtain 270 mg of 5'-O-DMTr-protected cyano-locked nucleoside 21 as a light yellow powder in a 100% yield. 1 H NMR(DMSO-d6,400MHz)δ12.14(s,1H),11.85(s,1H),8.11(s,1H),7.46(d,J=7.4 Hz,2H),7.33-7.21(m,7H),6.90(dd,J=8.8,1.4Hz,4H),6.26(d,J=4.2Hz,1H),6. 08(s,1H),5.08(s,1H),4.77(s,1H),4.57(d,J=4.2Hz,1H),3.74(s,6H),3.68(d, J=11.2Hz,1H),3.39(d,J=11.2Hz,1H),2.82-2.75(m,1H),1.14(d,J=6.8Hz,6H); 13 C NMR(DMSO-d6,100MHz)δ180.73,158.66,155.22,148.89,148.58,144.97,136.87,135.59,135.40,130.34,130.31,128.33,128.21,12 7.27,120.65,118.31,113.71,88.30,86.87,84.93,80.95,72.28,71.18,60.22,55.51,35.27,19.33,19.28; ESI-MS(m / z)691.36[MH] - .

[0187] twenty two

[0188] To a solution of nucleoside 21 (180 mg, 0.26 mmol) and 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (157 mg, 0.52 mmol) in 10 mL of dichloromethane was added 1H-tetrazole (15 mg, 0.21 mmol) at room temperature. The reaction was allowed to react for 12 h at room temperature. TLC analysis indicated that the reaction was complete (dichloromethane / ethyl acetate = 2 / 1). The reaction solution was directly purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-40%) to afford 180 mg of phosphoramidite 22 as a slightly yellow waxy solid in a 78% yield. 31 PNMR(152MHz,DMSO-d6)δ149.26,149.23; ESI-MS(m / z)893.40[M+H] + .

[0189] R-6'-CN-LNA- m Synthesis of C phosphoramidite monomer

[0190] The reaction conditions are as follows: (a) (1) TESCl, Et3N, acetonitrile, 0℃-room temperature, 3h; (2) 1,2,4-triazole, POCl3, acetonitrile, 0℃-room temperature, 2h; (3) NH4OH, 1,4-dioxane, room temperature, 2h; (b) (1) Bz2O, acetonitrile, room temperature, 20h; (2) TBAF, THF, room temperature, 12h; (c) 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite, 1H-tetrazole, dichloromethane, room temperature, 5h.

[0191] twenty three

[0192] To a solution of nucleotide 12 (5.0 g, 8.37 mmol) and triethylamine (23.3 mL, 167 mmol) in acetonitrile (100 mL) was added triethylsilyl chloride (7.0 mL, 41.8 mmol) at 0°C. The mixture was allowed to react at room temperature for 3 h. 1,2,4-Triazole (8.67 g, 125.55 mmol) was added to the reaction mixture, stirred for 10 min, and then cooled to 0°C. POCl₃ (2.34 mL, 25.11 mmol) was added dropwise to the reaction mixture, and the reaction was continued at room temperature for 2 h. The reaction was complete as determined by TLC (dichloromethane / methanol = 10 / 1). The reaction mixture was poured into 300 mL of ice water, extracted with ethyl acetate, washed sequentially with water, saturated sodium bicarbonate solution, and saturated brine, dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was dissolved in 60 mL of 1,4-dioxane, and 25% aqueous ammonia (6.25 mL, 92 mmol) was added. The mixture was stirred at room temperature for 2 h. The reaction solution was concentrated under reduced pressure and diluted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous NaSO, filtered, concentrated, and purified by flash column chromatography (gradient elution: methanol / dichloromethane = 0-15%) to afford 5.5 g of aminonucleoside 23 as a pale yellow solid in a 92% yield. 1 HNMR(DMSO-d6,400MHz)δ7.52-7.25(m,12H),6.96-6.91(m,6H),5.66(s,1H),4.93(s,1H),4.45(s,1H),4.40(s,1H) ,3.75(s,6H),3.54(d,J=11.2Hz,1H),3.41(d,J=11.2Hz,1H),1.72(s,3H),0.78(t,J=7.9Hz,9H),0.53-0.41(m,6H); 13 C NMR(DMSO-d6,100MHz)δ166.09,158.81,158.79,154.95,144.78,136.54,135.38,135.17,130.30,130.14,128.43,128.07,127.46,11 7.58,113.81,113.77,101.92,88.29,87.59,86.82,80.77,71.60,71.09,58.50,55.55,14.01,6.78,4.42; ESI-MS(m / z)733.31[M+Na] + .

[0193] twenty four

[0194] To a solution of aminonucleoside 23 (5.5 g, 7.73 mmol) in acetonitrile (60 mL) was added benzoic anhydride (3.85 g, 12 mmol). After stirring at room temperature for 20 h, the reaction was quenched with 5 mL of water. TBAF (4.38 g, 19.3 mmol) was added to the reaction mixture, which was stirred at room temperature for 12 h. The pH was adjusted to 10 by adding 15% NaOH, and stirring was continued for 3 h. The reaction solution was diluted with ethyl acetate and washed with water. The organic layer was washed with water and saturated brine, dried over anhydrous Na2SO4, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-40%) to afford 3.1 g of 5'-O-DMTr-protected nucleoside 24 as a white foamy solid in a 57% yield. 1 H NMR(DMSO-d6,400MHz)δ13.06(br s,1H),8.19(s,2H),7.69-7.25(m,13H),6.94(d,J=8.3Hz,4H),6.32(s,1H),5.70(s,1H),5.06(s,1 H),4.53(s,1H),4.38(d,J=4.1Hz,1H),3.73(d,J=11.0Hz,1H),3.40(d,J=11.0Hz,1H),1.84(s,3H); 13 C NMR(DMSO-d6,100MHz)δ178.64,159.43,158.75,147.49,144.93,137.11,135.53,135.32,133.07,130.37,130.32,129.85,128.83, 128.46,128.21,127.41,117.77,113.82,110.12,88.75,87.28,80.55,71.06,70.70,58.88,55.56,13.66; ESI-MS(m / z)701.32[M+H] + .

[0195] 25

[0196] To a solution of nucleoside 24 (1.7 g, 2.42 mmol) and 2-cyanoethyl N,N,N',N'-tetraisopropylphosphoramidite (1.1 g, 3.63 mmol) in 20 mL of anhydrous dichloromethane was added 1H-tetrazole (135 mg, 1.94 mmol). After reacting at room temperature for 5 h, saturated NaHCO3 solution was added to the reaction solution, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated brine, dried over MgSO4, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-20%) to give 1.83 g of phosphoramidite 25 as a white foamy solid in a yield of 84%. 31PNMR(152MHz,DMSO-d6)δ149.20,148.47; ESI-MS(m / z)901.46[M+H] + .

[0197] Part II: Synthesis of S-6'-CN-LNA

[0198] Synthesis of S-6'-Allyl-LNA

[0199] The reaction conditions are as follows: (a) 2-iodobenzoic acid, acetonitrile, reflux, 11 h; (b) NaBH4, LiCl, MeOH, -40°C, 8 h; (c) methylsulfonyl chloride, DMAP, pyridine, room temperature, 32 h; (d) (1) FeCl3·6H2O, dichloromethane, 0°C-room temperature, 3 h; (2) Ac2O, DMAP, pyridine, dichloromethane, room temperature, 4 h.

[0200] 26

[0201] To a solution of compound 2 (105 g, 0.164 mol) in 500 mL of acetonitrile was added 2-iodoacetylbenzoic acid (69 g, 0.25 mol), and the mixture was heated to reflux for 6 h. 2-iodoacetylbenzoic acid (13.8 g, 0.05 mol) was then added again, and the reaction was continued at reflux for 5 h. The reaction was complete after TLC (petroleum ether / ethyl acetate = 5 / 1). The reaction solution was filtered through celite, and the filtrate was concentrated and purified by flash column chromatography (gradient elution: ethyl acetate / petroleum ether = 0-20%) to give 93 g of a colorless viscous product 26, in an 89% yield. 1 H NMR(CDCl3,400MHz)δ7.85-7.70(m,4H),7.60-7.53(m,4H),7.48-7.45(m,2H),7.40-7.27( m,7H),6.08(d,J=4.0Hz,1H),5.98-5.83(m,1H),5.13-5.01(m,2H),4.90(d,J=12.0Hz,1H) ,4.86(t,J=8.0,4.0Hz,1H),4.63(d,J=12.0Hz,1H),4.23(d,J=8.0Hz,1H),3.92(d,J=12.0 Hz,1H),3.72(d,J=12.0Hz,1H),3.66-3.55(m,2H),1.61(s,3H),1.43(s,3H),0.98(s,9H); 13C NMR(CDCl3,100MHz)δ207.44,135.53,134.92,134.83,133.23,133.06,132 .49,132.46,130.73,129.99,129.91,128.12,127.97,127.87,127.75,127. 71,126.57,126.09,125.93,125.82,118.44,114.93,106.94,96.44,81.14 ,80.15,73.55,44.95,27.61,26.81,26.68,19.13; ESI-MS(m / z)635.40[MH] - .

[0202] 27

[0203] At room temperature, a solution of compound 26 (108 g, 0.17 mol) in 400 mL of tetrahydrofuran was added with a solution of lithium chloride (18 g, 0.424 mol) in 200 mL of methanol. The reaction solution was cooled to -40°C, and sodium borohydride (4.3 g, 0.113 mol) was added. After reacting for 4 h, sodium borohydride (4.3 g, 0.113 mol) was added and the reaction was continued for another 4 h. The reaction was complete by TLC (petroleum ether / ethyl acetate = 5 / 1). The reaction solution was poured into a beaker and quenched with saturated ammonium chloride solution (100 mL). The mixture was stirred until no bubbles were generated, extracted with ethyl acetate (1 L), washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / petroleum ether = 0-20%) to give 90 g of colorless viscous product 27 in an 83% yield. 1 H NMR(CDCl3,400MHz)δ7.86-7.79(m,4H),7.59-7.57(m,2H),7.51-7.46(m,5H),7.41-7.28( m,6H),5.91-5.83(m,2H),5.01-4.97(m,3H),4.78(dd,J=5.3,3.9Hz,1H),4.65(d,J=12.0Hz ,1H),4.51(d,J=5.4Hz,1H),4.19(dd,J=10.0,2.1Hz,1H),3.76(d,J=10.7Hz,1H),3.54(d,J =10.7Hz,1H),2.36-2.31(m,1H),2.09-2.02(m,1H),1.67(s,3H),1.39(s,3H),0.91(s,9H); 13C NMR(CDCl3,100MHz)δ136.40,135.53,135.51,134.80,133.22,132.16,1 32.88,132.74,129.85,129.78,128.41,127.94,127.78,126.85,126.29 ,126.14,125.67,161.13,114.38,104.73,90.15,79.74,78.12,72.80,7 1.04,64.51,35.91,26.98,26.81,26.75,19.11; ESI-MS(m / z)637.41[MH] - .

[0204] 28

[0205] Compound 27 (90 g, 0.14 mol) and DMAP (1.71 g, 14 mmol) were dissolved in 400 mL of pyridine, and methanesulfonyl chloride (16.4 mL, 0.21 mmol) was added dropwise. The mixture was allowed to react at room temperature for 20 h. Methanesulfonyl chloride (5.5 mL, 0.07 mol) was then added and the reaction continued for 12 h. The reaction was complete by TLC (petroleum ether / ethyl acetate = 5 / 1). 50 mL of methanol was added to the reaction solution to quench the reaction, and the solution was concentrated under reduced pressure to remove excess pyridine. The residue was diluted with ethyl acetate, washed sequentially with water, 1N HCl solution, and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford 100 g of methanesulfonyl compound 28 as a slightly yellowish viscous substance in a 100% yield. 1 H NMR(DMSO-d6,400MHz)δ7.95-7.87(m,4H),7.59-7.38(m,13H),5.85(d,J=4.0Hz,1H),5.6 8-5.58(m,1H),5.13(dd,J=9.8,1.4Hz,1H),5.07(t,J=5.0Hz,1H),4.98-4.91(m,3H),4.69 (d,J=11.8Hz,1H),4.47(d,J=5.4Hz,1H),3.76(d,J=10.8Hz,1H),3.71(d,J=10.8Hz,1H), 3.08(s,3H),2.83-2.78(m,1H),2.16-2.08(m,1H),1.58(s,3H),1.37(s,3H),0.88(s,9H); 13C NMR(CDCl3,100MHz)δ135.54,135.59,135.30,134.36,133.24,133.15,132.7 2,132.68,130.50,130.47,128.58,128.43,128.35,128.21,127.32,126.79, 126.61,126.48,118.25,124.07,105.02,88.46,85.65,79.89,77.62,72.51, 63.50,36.01,27.06,26.95,26.82,26.58,19.07; ESI-MS(m / z)734.39[M+NH4] + ,739.34[M+Na] + .

[0206] 29

[0207] A 1000 mL dichloromethane solution of compound 28 (100 g, 0.14 mol) was cooled to 0°C, and ferric chloride hexahydrate (15.1 g, 56 mmol) was added. After the addition was complete, the mixture was allowed to react at room temperature for 3 h. The reaction was monitored by TLC (petroleum ether / ethyl acetate = 4 / 1). The reaction solution was poured into 2 L of water and extracted with dichloromethane. The organic layer was washed with water, saturated sodium bicarbonate solution, and saturated brine in sequence, dried over anhydrous magnesium sulfate, filtered, concentrated under reduced pressure, and dried in vacuo. The resulting viscous material was dissolved in 1 L of dichloromethane, and pyridine (113 mL, 1.4 mol) and DMAP (2.56 g, 21 mol) were added in sequence. Acetic anhydride (79 mL, 0.84 mol) was then added dropwise. The mixture was allowed to react at room temperature for 4 h. The reaction was monitored by TLC (petroleum ether / ethyl acetate = 4 / 1). The reaction solution was poured into 2 L of water and extracted with dichloromethane. The organic layer was washed sequentially with water, 1N HCl solution, saturated sodium bicarbonate solution, and saturated brine, dried over anhydrous magnesium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: petroleum ether / ethyl acetate = 0-60%) to obtain 95 g of a mixture of diacetyl compound 29 as a colorless viscous product in an 89% yield. ESI-MS (m / z) 778.39 [M+NH4] + ,783.44[M+Na] + .

[0208] Reaction conditions were as follows: (a) thymine, N,O-bis(trimethylsilyl)acetamide (BSA), TMSOTf, acetonitrile, 80°C, 3 h; (b) K2CO3, MeOH, room temperature, 16 h; (c) N6-benzoyl adenine, BSA, TMSOTf, toluene, 100°C, 3 h; (d) 6-chloroguanine, BSA, TMSOTf, toluene, 100°C, 3 h.

[0209] 30

[0210] To a suspension of thymine (7.6 g, 60 mmol) in 50 mL of acetonitrile was added BSA (29 mL, 120 mmol) and stirred at room temperature for 20 min until the thymine dissolved. After the system became clear, a solution of diacetylated sugar 29 (23 g, 30 mmol) in 200 mL of acetonitrile was added, followed by rapid dropwise addition of TMSOTf (8.3 mL, 45 mmol). After the addition was complete, the temperature was raised to 80 ° C and the reaction was stirred for 3 h. The reaction was monitored by TLC (petroleum ether / ethyl acetate = 5 / 1) to determine completion. Heating was stopped, and after the reaction solution cooled to room temperature, the reaction solution was poured into ethyl acetate, to which was added a half-saturated NaHCO solution (400 mL) and stirred for 20 min. The insoluble solid was filtered off with celite, the organic layer was separated, and then washed with water and saturated brine in sequence, dried over anhydrous NaSO, filtered, concentrated, and dried in vacuo. The resulting residue was dissolved in 250 mL of methanol, to which KCO (12.4 g, 90 mmol) was added, and the reaction was allowed to react at room temperature for 16 h. TLC detection showed that the reaction was complete (dichloromethane / ethyl acetate = 10 / 3). After the reaction solution was concentrated, the residue was extracted with ethyl acetate, washed with water and saturated brine in sequence, dried over anhydrous NaSO, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-25%) to obtain 15.4 g of locked nucleic acid derivative 30 as a white foamy solid in a yield of 75%. 1H NMR(CDCl3,400MHz)δ8.92(br s,1H),7.84-7.64(m,8H),7.51-7.29(m,10H),5.77-5.59(m,1H),5.65(s,1H),5.01-4.96(m,2H),4.84(d,J=11.4Hz,1H),4 13C NMR(CDCl3,100MHz)δ163.79,149.75,135.59,135.35,134.36,134.13,134.01,1 33.14,133.10,132.80,132.34,130.11,130.06,128.45,127.99,127.95,127.87, 127.75,126.91,126.45,126.30,125.75,117.38,110.34,89.58,87.12,84.02,7 6.90,72.53,59.27,35.33,29.72.26.94,19.44,12.15; ESI-MS(m / z)689.43[M+H] + ,711.34[M+Na] + .

[0211] 31

[0212] To a suspension of N6-benzoyl adenine (6.1 g, 25.5 mmol) in 25 mL of toluene was added BSA (17 mL, 68 mmol), and the mixture was heated to 60°C until the N6-benzoyl adenine dissolved and the system became clear. The reaction solution was then cooled to room temperature, and a solution of diacetylated sugar 29 (13 g, 17 mmol) in 70 mL of toluene was added. TMSOTf (4.63 mL, 25.5 mmol) was then quickly added dropwise. After the addition was complete, the temperature was raised to 100°C, and the reaction was stirred for 3 h. The reaction was monitored to be complete by TLC (petroleum ether / ethyl acetate = 5 / 1). Heating was discontinued, and after the reaction solution cooled to room temperature, it was poured into ethyl acetate and a semi-saturated NaHCO solution (400 mL) was added. The mixture was stirred for 20 min, and the insoluble solid was removed by filtration through celite. The organic layer was separated and washed sequentially with water and saturated brine, dried over anhydrous NaSO, filtered, concentrated, and dried under vacuum. The mixture was then purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-40%) to obtain 9.1 g of the nucleoside product, in a yield of 74%. ESI-MS (m / z) was 940.04 [M+H]. + .

[0213] The above product (8.5 g, 9 mmol) was dissolved in 90 mL of methanol, and KCO (6.25 g, 45 mmol) was added. The reaction was allowed to react at room temperature for 16 h. The reaction was complete by TLC (dichloromethane / ethyl acetate = 10 / 3). The reaction solution was concentrated, and the residue was extracted with ethyl acetate, washed sequentially with water and saturated brine, dried over anhydrous NaSO, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-100%) to obtain 4.9 g of locked nucleic acid derivative 31 as a white powdery solid in a yield of 78%. 1 H NMR(CDCl3,400MHz)δ8.27(s,1H),7.98(s,1H),7.81-7.67(m,7H),7.62(s,1H),7.49-7.31(m,9H),6.02(s,1H), 5.86-5.76(m,3H),5.06-5.02(m,2H),4.95(s,1H),4.74(d,J=11.6Hz,1H),4.66(d,J=11.6Hz,1H),4.27(s,1H),4.18(d d,J=9.3,4.6Hz,1H),4.09(d,J=11.9Hz,1H),4.05(d,J=11.9Hz,1H),2.77-2.69(m,1H),2.36-2.30(m,1H),1.07(s,9H); 13 C NMR(CDCl3,100MHz)δ155.16,152.74,148.84,138.22,135.69,135.63,134.35, 134.40,133.10,133.06,132.79,132.62,129.99,129.97,128.36,127.92,127. 85,127.82,127.71,126.92,126.32,126.19,125.64,120.14,117.16,89.04,86 .48,84.57,78.06,72.72,59.50,35.31,26.78,19.27; ESI-MS(m / z)698.36[M+H] + .

[0214] 32

[0215] To a suspension of 6-chloroguanine (3.34 g, 19.7 mmol) in 25 mL of toluene was added BSA (13 mL, 52.6 mmol), and the mixture was heated to 60°C until 6-chloroguanine dissolved and the system became clear. The reaction solution was then cooled to room temperature, and a 75 mL toluene solution of diacetylated sugar 29 (10 g, 13.1 mmol) was added. TMSOTf (3.6 mL, 19.7 mmol) was then added dropwise rapidly. After the addition was complete, the temperature was raised to 100°C, and the reaction was stirred for 3 h. The reaction was monitored for completion by TLC (petroleum ether / ethyl acetate = 5 / 1). Heating was stopped, and after the reaction solution cooled to room temperature, the reaction solution was poured into ethyl acetate, to which was added a half-saturated NaHCO solution (400 mL) and stirred for 20 min. The insoluble solid was filtered off with celite, the organic layer was separated, and then washed with water and saturated brine in sequence, dried over anhydrous NaSO, filtered, concentrated, and dried in vacuo. The resulting residue was dissolved in 100 mL of methanol, to which KCO (7.25 g, 52.6 mmol) was added, and the reaction was allowed to react at room temperature for 16 h. TLC detection showed that the reaction was complete (dichloromethane / ethyl acetate = 10 / 3). After the reaction solution was concentrated, the residue was extracted with ethyl acetate, washed with water and saturated brine in sequence, dried over anhydrous NaSO, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-30%) to obtain 6.07 g of locked nucleic acid derivative 32 as a white foamy solid in a yield of 63%. 1 H NMR(CDCl3,400MHz)δ7.82-7.65(m,9H),7.49-7.30(m,9H),5.91(s,1H),5.85-5.76(m,1H),5.06-5.02(m,2H),4.86(br s,2H),4.81(s,1H),4.73(d,J=11.5Hz,1H),4.64(d,J=11.5Hz,1H),4.27(s, 1H),,4.09-4.01(m,5H),2.76-2.69(m,1H),2.35-2.28(m,1H),1.07(s,9H); 13C NMR(CDCl3,100MHz)δ161.48,159.29,152.47,135.70,135.55,134.47,124.36 ,133.12,133.04,132.74,132.58,129.98,129.95,128.34,127.91,127.88,127 .84,127.70,126.60,125.59,117.15,116.13,88.77,86.19,84.49,78.23,77. 15,72.78,55.50,53.90,35.31,29.75,26.76,19.24; ESI-MS(m / z)728.39[M+H] + .

[0216] Synthesis of S-6'-CN-LNA

[0217] The reaction conditions are as follows: (a)(1) tris(triphenylphosphine)carbonylruthenium(II) hydrochloride, EtOH, 80°C, 12-48h; (b) potassium osmate dihydrate, 50% NMO, THF, t-BuOH, H2O, 60°C, 8-12h; (c) NaIO4, EtOH-THF (2 / 1 v / v), H2O, room temperature, 12h; (d) NH4OH, I2, room temperature, THF, EtOH, 24h.

[0218] 33

[0219] To a solution of allyl nucleoside derivative 30 (10.0 g, 14.5 mmol) in 120 mL of anhydrous ethanol was added tris(triphenylphosphine)carbonylruthenium(II) chloride (345 mg, 0.36 mmol, 2.5% mol), and the temperature was raised to 80°C for 12 h. The reaction solution was directly concentrated, and the residue was dissolved in 80 mL of tetrahydrofuran. 10 mL of tert-butanol and 10 mL of water, potassium osmate dihydrate (26.7 mg, 72.6 μmol, 0.5% mol), and 50% N-methylmorpholine-N-oxide (4.53 mL, 10.9 mmol) were added in sequence. The temperature was raised to 60°C for 8 h. The reaction was complete when detected by TLC (dichloromethane / methanol = 10 / 1). The reaction was quenched with saturated sodium sulfite solution, extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-60%) to obtain 9.3 g of a mixed dihydroxylated isomeric product.

[0220] The bishydroxylated product was dissolved in 60 mL of ethanol-tetrahydrofuran solution, and a 10 mL aqueous solution of NaIO4 (3.32 g, 15.5 mmol) was added dropwise. The mixture was stirred at room temperature for 12 h. After filtering out the insoluble solid, 25% aqueous ammonia (5.5 mL, 72.6 mmol) was added to the filtrate. I2 (1.84 g, 7.26 mmol) was then added portionwise and allowed to react at room temperature for 24 h. The reaction was quenched with saturated sodium sulfite solution, extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-30%) to afford 33 as a slightly yellowish foamy solid (37% yield). 1 H NMR(CDCl3,400MHz)δ8.87(br s,1H),7.82-7.74(m,4H),7.68-7.63(m,4H),7.50-7.29(m,9H),7.18(d,J=1.2Hz,1H),5.62(s,1H),4.93(d,J=11.8Hz,1H),4.85(s,1H ),4.76(d,J=11.8Hz,1H),4.69(s,1H),4.30(d,J=12.2Hz,1H),4.25(d,J=12.2Hz,1H),4.07(s,1H),1.58(d,J=1.2Hz,3H),1.08(s,9H); 13 C NMR(CDCl3,100MHz)δ163.31,149.51,135.49,135.36,133.37,133.33,133 .14,133.11,132.21,131.87,130.27,130.23,128.55,128.01,127.72,126 .90,126.43,126.35,125,44,114.18,111.17,90.08,87.22,78.12,76.00, 72.69,69.48,60.40,58.82,26.83,19.40,12.18; ESI-MS(m / z)674.28[M+H] + .

[0221] 34

[0222] To a solution of the allyl nucleoside derivative 31 (4.9 g, 7.0 mmol) in 50 mL of ethanol was added tris(triphenylphosphine)carbonylruthenium(II) hydrochloride (167 mg, 0.175 mmol, 2.5% mol), and the mixture was heated to 80°C for 36 h. The reaction solution was directly concentrated, and the residue was dissolved in 40 mL of tetrahydrofuran. 5 mL of tert-butanol, 5 mL of water, potassium osmate dihydrate (26 mg, 70 μmol, 1% mol), and 50% N-methylmorpholine-N-oxide (2.2 mL, 10.5 mmol) were added sequentially, and the mixture was heated to 60°C for 8 h. The reaction was quenched with saturated sodium sulfite solution, extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the residue purified by flash column chromatography (gradient elution: ethyl acetate containing 5% methanol / dichloromethane = 0-100%) to afford 3.6 g of a mixed bishydroxylated isomeric product. The above-mentioned bishydroxylation product was dissolved in 40 mL of ethanol-tetrahydrofuran solution, and 8 mL of aqueous solution of NaIO4 (1.58 g, 7.4 mmol) was added dropwise thereto, and stirred at room temperature for 12 h. After filtering out the insoluble solid, 25% aqueous ammonia (3.05 mL, 49.2 mmol) was added to the filtrate, and then I2 (1.25 g, 4.92 mmol) was added portionwise and allowed to react at room temperature for 24 h. The reaction was quenched with saturated sodium sulfite solution, extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate containing 5% methanol / dichloromethane = 0-60%) to give 1.6 g of product 34 as a white foamy solid in a yield of 48%. 1 H NMR(CDCl3,400MHz)δ8.22(s,1H),7.80-7.75(m,3H),7.70-7.66(m,6H),7.48-7.31(m,9H),5.96(s,1H),5.85(br s,2H),5.19(s,1H),4.88-4.77(m,3H),4.36(s,1H),4.32(d,J=12.2Hz,1H),4.19(d,J=12.2Hz,1H),1.06(s,9H); 13 C NMR (CDCl3, 100MHz) δ155.43,153.10,148.62,135.58,130.12,128.48,127.98,127.91,127.89,127.70,126.83,126. 33,125.47,119.91,114.52,89.84,86.36,78.22,75.52,72.86,70.11,59.39,29.70,19.27; ESI-MS(m / z)683.35[M+H] + .

[0223] 35

[0224] To a solution of allyl nucleoside derivative 32 (7.2 g, 10 mmol) in 120 mL of anhydrous ethanol was added tris(triphenylphosphine)carbonylruthenium(II) hydrochloride (238 mg, 0.25 mmol, 2.5% mol), and the temperature was raised to 80°C for 48 h. The reaction solution was directly concentrated, and the residue was dissolved in 50 mL of tetrahydrofuran. 10 mL of tert-butanol and 10 mL of water, potassium osmate dihydrate (36 mg, 10 μmol, 1% mol), and 50% N-methylmorpholine-N-oxide (4.0 mL, 20 mmol) were added in sequence. The temperature was raised to 60°C for 8 h. The reaction was complete when detected by TLC (dichloromethane / methanol = 10 / 1). The reaction was quenched with saturated sodium sulfite solution, extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-40%) to obtain 5.6 g of a mixed dihydroxylated isomeric product.

[0225] The above-mentioned bishydroxylation product was dissolved in 60 mL of ethanol-tetrahydrofuran solution, and a 10 mL aqueous solution of NaIO4 (3.54 g, 7.35 mmol) was added dropwise thereto, and the mixture was stirred at room temperature for 12 h. After filtering out the insoluble solid, 25% aqueous ammonia (5.5 mL, 73.5 mmol) was added to the filtrate, and then I2 (1.87 g, 7.35 mmol) was added portionwise and allowed to react at room temperature for 24 h. The reaction was quenched with saturated sodium sulfite solution, extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-40%) to give 2.5 g of product 35 as a white foamy solid in a yield of 48%. 1 H NMR(CDCl3,400MHz)δ7.80-7.66(m,8H),7.58(s,1H),7.47-7.31(m,9H),5.86(s,1H),5.03(s,1H),4.8 1-4.76(m,5H),4.34(s,1H),4.31(d,J=12.2Hz,1H),4.19(d,J=12.2Hz,1H),4.06(s,3H),1.06(s,9H); 13C NMR(CDCl3,100MHz)δ161.63,159.37,152.27,136.01,135.60,135.58,1 33.75,133.11,132.19,132.16,130.13,128.49,127.99,127.96,127.69, 126.67,126.31,126.23,125.38,115.99,114.61,89.67,86.10,78.31,77 .64,72.91,70.05,59.41,53.97,26.70,19.25; ESI-MS(m / z)713.40[M+H] + .

[0226] Synthesis of S-6'-CN-LNA phosphoramidite monomer

[0227] Synthesis of S-6'-CN-LNA-T Phosphoramidite Monomer

[0228] The reaction conditions are as follows: (a) (1) DDQ, dichloromethane-H2O (20 / 1), room temperature, 24 h; (2) Et3N, Et3N·3HF, THF, room temperature, 12 h; (b) DMTrCl, pyridine, room temperature, 12 h; (c) 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite, 1H-tetrazolyl tetrazolium, room temperature, 5 h.

[0229] 36

[0230] At room temperature, DDQ (420 mg, 1.86 mmol) was added to a mixture of nucleoside derivative 33 (3.6 g, 5.34 mmol) in 42 mL of dichloromethane-water (20:1). The mixture was allowed to react at room temperature for 24 h. The reaction was complete by TLC (dichloromethane / ethyl acetate = 10 / 1). The reaction solution was concentrated under reduced pressure, extracted with ethyl acetate, washed sequentially with saturated sodium sulfite solution, sodium bicarbonate solution, and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was dissolved in 50 mL of tetrahydrofuran, and triethylamine (1.78 mL, 13.35 mmol) and triethylamine trihydrofluoride (2.61 mL, 16 mmol) were added sequentially. The reaction was allowed to react at room temperature for 12 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). 10 g of solid sodium bicarbonate was added to the reaction solution, and the mixture was stirred until no bubbles were generated. The reaction solution was concentrated under reduced pressure and directly purified by flash column chromatography (gradient elution: methanol / dichloromethane = 0-20%) to give 1.1 g of slightly yellowish white solid 36 in a yield of 70%. 1H-NMR(400MHz,MeOH-d4)δ7.62(s,1H),5.86(s,1H),4.78(s,1H),4.53(s,1H ),4.22(s,1H),4.17(d,J=12.0Hz,1H),4.13(d,J=12.0Hz,1H),1.89(s,3H); 13 C-NMR(100MHz,MeOH-d4)δ164.97,150.36,134.89,114.74,109.74,90.36,86.75,80.78,69.56,68.45,55.87.11.19; ESI-MS(m / z)296.13[M+H] + The crystal structure of S-6'-CN-LNA-T monomer (compound 36) is shown in FIG8 .

[0231] 37

[0232] To a solution of cyano-locked nucleoside derivative 36 (2.0 g, 6.77 mmol) in 15 mL of pyridine was added 4,4'-dimethoxytrityl chloride (3.4 g, 10 mmol). The mixture was stirred at room temperature for 12 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). The reaction was quenched with 50 mL of methanol and concentrated under reduced pressure. The residue was diluted with ethyl acetate, washed sequentially with water and saturated brine, dried over Na2SO4, concentrated, and purified by flash column chromatography (gradient elution: methanol / dichloromethane = 0-10%) to afford 2.6 g of 5'-O-DMTr-protected nucleoside 37 as a white solid in a 64% yield. 1 H-NMR(400MHz,DMSO-d6)δ11.44(s,1H),7.46-7.24(m,10H),6.92(dd,J=6.0,1.4Hz,4H),6.30(s,1H),5.5 3(s,1H),5.11(s,1H),3.79(d,J=7.9Hz,1H),3.74(s,6H),3.49(d,J=7.4Hz,1H),1.60(s,3H); 13C-NMR(10 0MHz,DMSO-d6)δ162.66,157.16,148.78,143.44,134.16,133.74,132.93,128.73,128.65,126.87,126.5 4,126.80,114.35,112.20,107.85,87.62,85.06,84.89,79.26,68.84,67.42,57.44,53.97,11.15; ESI-MS 620.20(m / z)[M+Na] + .

[0233] 38

[0234] To a solution of nucleoside 37 (2.0 g, 3.35 mmol) and 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (1.51 g, 5 mmol) in 20 mL of dichloromethane was added 1H-tetrazole (230 mg, 3.35 mmol). The mixture was allowed to react at room temperature for 5 h. The reaction was complete as determined by TLC (ethyl acetate / dichloromethane = 5 / 1). Saturated NaHCO3 solution was added to the reaction solution, which was extracted with dichloromethane, washed with saturated brine, dried over MgSO4, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-20%) to afford 2.1 g of phosphoramidite 38 as a white foamy solid in a 79% yield. 31 P-NMR(152MHz,DMSO-d6)δ148.95,148.35; ESI-MS(m / z)798.33[M+H] + .

[0235] Synthesis of S-6'-CN-LNA-A Phosphoramidite Monomer

[0236] The reaction conditions are as follows: (a) BzCl, pyridine, room temperature, 6 h; (b) (1) DDQ, dichloromethane-H2O (20 / 1), room temperature, 24 h; (2) Et3N, Et3N·3HF, THF, room temperature, 12 h; (b) DMTrCl, pyridine, room temperature, 8 h; (c) 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite, 1H-tetrazole, room temperature, 8 h.

[0237] 39

[0238] Benzoyl chloride (422 μL, 3.66 mmol) was added dropwise to a solution of nucleoside 34 (1.0 g, 1.46 mmol) in 5 mL of pyridine at room temperature. After reacting at room temperature for 4 h, benzoyl chloride (100 μL, 0.87 mmol) was added to the reaction solution and the reaction continued for 2 h. 15% NaOH was added dropwise to adjust the pH to 8, and the solution was stirred at room temperature for 2 h. The solution was diluted with ethyl acetate and washed sequentially with water, 1N HCl solution, and saturated brine. The product was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-45%) to afford 1.05 g of a slightly yellow foamy solid in a 91% yield. 1H NMR(CDCl3,400MHz)δ9.02(br s,1H),8.65(s,1H),8.03(d,J=7.2Hz,2H),7.99(s,1H),7.79-7.34(m,20H),6.03(s,1H),5.19(s,1H),4.89(s ,1H),4.87(d,J=12.2Hz,1H),4.82(d,J=12.2Hz,1H),4.34-4.31(m,2H),4.19(d,J=12.2Hz,1H),1.06(s,9H); 13 C NMR(CDCl3,100MHz)δ164.60,152.64,150.42,149.70,140.19,135.55,133.53,133 .42,133.09,132.99,132.12,132.09,130.15,128.94,128.52,128.00,127.92,127. 91,127.85,127.69,126.80,126.38,126.28,125.42,123.29,114.42,90.04,86.43 ,78.19,77.54,72.97,70.17,59.42,29.70,26.70,19.26; ESI-MS(m / z)787.32[M+H] + .

[0239] 40

[0240] At room temperature, DDQ (780 mg, 3.44 mmol) was added to a mixture of nucleoside derivative 39 (900 mg, 1.14 mmol) in 10 mL of dichloromethane-water (20:1). The mixture was allowed to react at room temperature for 24 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). The reaction solution was concentrated under reduced pressure, extracted with ethyl acetate, washed sequentially with saturated sodium sulfite solution, sodium bicarbonate solution, and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was dissolved in 15 mL of tetrahydrofuran, and triethylamine (400 μL, 2.85 mmol) and triethylamine trihydrofluoride (550 μL, 3.42 mmol) were added sequentially. The reaction was allowed to react at room temperature for 12 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). 1.0 g of sodium bicarbonate solid was added to the reaction solution, and the mixture was stirred until no bubbles were generated. The reaction solution was concentrated under reduced pressure and directly purified by flash column (gradient elution: dichloromethane / methanol = 0-20%) to obtain 340 mg of cyano-locked nucleoside 40 with a yield of 73%. 1 H NMR(CD3OD,400MHz)δ; ESI-MS(m / z)409.19[M+H] +,431.16[M+Na] + .

[0241] 41

[0242] To a solution of cyano-locked nucleoside 40 (300 mg, 0.735 mmol) in 5 mL of pyridine was added 4,4'-dimethoxytrityl chloride (373 mg, 1.1 mmol) at room temperature and stirred at room temperature for 8 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). The reaction was quenched with 1 mL of methanol and concentrated under reduced pressure. The residue was diluted with ethyl acetate, washed sequentially with water and saturated brine, dried over Na2SO4, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate containing 5% methanol / dichloromethane = 0-80%) to afford 330 mg of 5'-O-DMTr-protected cyano-locked nucleoside 41 as a light yellow solid in a 64% yield. 1 H NMR(DMSO-d6,400MHz)δ11.26(br s,1H),8.79(s,1H),8.54(s,1H),8.06(d,J=7.3Hz,2H),7.67(t,J=7.3Hz,1H),7.57 (t,J=7.8Hz,2H),7.46(d,J=7.4Hz,2H),7.34-7.24(m,6H),7.25(t,J=7.2Hz,1H),6 .90(d,J=8.9Hz,4H),6.33(d,J=3.5Hz,1H),6.23(s,1H),5.36(s,1H),4.92(s,1H), 4.70(d,J=3.5Hz,1H),3.85(d,J=11.1Hz,1H),3.74(s,6H),3.47(d,J=11.1Hz,1H); 13 C NMR(DMSO-d6,100MHz)δ166.10,158.64,152.33,152.02,150.97,145.07,142.33,135.88,135.38,130.25,130.19,128.98,128.96, 128.36,128.12,126.03,116.03,113.73,113.69,89.29,86.26,85.39,81.12,71.78,69.40,60.09,55.52; ESI-MS(m / z)711.37[M+H] + .

[0243] 42

[0244] To a solution of nucleoside 41 (240 mg, 0.34 mmol) and 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (203 mg, 0.75 mmol) in 10 mL of dichloromethane was added 1H-tetrazole (21 mg, 0.3 mmol) at room temperature. The reaction was allowed to react for 8 h at room temperature. TLC analysis (dichloromethane / methanol = 15 / 1) confirmed the reaction was complete. The reaction solution was directly purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-40%) to afford 280 mg of phosphoramidite 42 as a slightly yellowish foamy solid in a 90% yield. 31 P NMR(152MHz,DMSO-d6)δ149.56,149.25; ESI-MS(m / z)909.38[MH] - .

[0245] Synthesis of S-6'-CN-LNA-G Phosphoramidite Monomer

[0246] The reaction conditions are as follows: (a) 2N HCl, THF-CH3OH (1 / 1), 60°C, 24h; (b) isobutyryl chloride, Et3N, DMAP, toluene, 100°C, 12h; (c) (1) DDQ, dichloromethane-H2O (20 / 1), room temperature, 24h; (2) Et3N, Et3N·3HF, THF, room temperature, 12h; (d) DMTrCl, pyridine, room temperature, 12h; (e) 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite, 1H-tetrazole, room temperature, 6h.

[0247] 43

[0248] To a solution of cyano-locked nucleoside 35 (2.2 g, 3.08 mmol) in tetrahydrofuran-methanol (1 / 1 v / v) was added 15.4 mL of 2N hydrochloric acid solution, and the mixture was heated to 60° C. for 24 h. The reaction was complete when detected by TLC (dichloromethane / ethyl acetate = 2 / 1). The product was extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: methanol / dichloromethane = 0-10%) to afford 1.48 g of guanosine 43 as a white solid in a 69% yield. 1 H NMR(CDCl3,400MHz)δ11.94(br s,1H),7.72-7.64(m,9H),7.48-7.16(m,10H),6.53(br s,2H),5.75(s,1H),4.81-4.70(m,3H),4.28-4.25(m,2H),4.17(d,J=12.2Hz,1H),1.03(s,9H); 13C NMR(CDCl3,100MHz)δ158.96,153.85,150.40,135.56,133.07,133.03,132.17,132.13,130.15,129.06,128.41,128.25,128.02,127.91,127.6 6,126.67,126.34,126.26,125.41,125.33,117.21,114.58,89.76,85. 91,78.28,72.87,69.98,59.39,26.72,19.28; ESI-MS(m / z)699.29[M+H] + .

[0249] 44

[0250] To a solution of guanosine 43 (1.2 g, 1.72 mmol) in 12 mL of toluene were added DMAP (105 mg, 0.86 mmol) and triethylamine (718 μL, 5.16 mmol), followed by isobutyryl chloride (550 μL, 5.16 mmol). The mixture was heated to 100°C and allowed to react for 12 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). Heating was stopped, and the reaction solution was cooled to room temperature. 1 mL of methanol was added to quench the reaction, and the solution was extracted with ethyl acetate. The solution was washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-80%) to afford 1.1 g of isobutyryl-protected guanosine 44 as a slightly yellow foamy solid in 83% yield. 1 H NMR(CDCl3,400MHz)δ11.97(s,1H),8.78(s,1H),7.75-7.60(m,9H),7.44-7.32(m,9H),5.60(s,1H),4.79(d,J=12.0Hz,1H),4.69(s,1 H),4.65(d,J=12.0Hz,1H),4.62(s,1H),4.27(d,J=12.3Hz,1H),4.18-4.14(m,2H),2.68-2.61(m,1H),1.28-1.24(m,6H),1.06(s,9H); 13C NMR(CDCl3,100MHz)δ178.64,155.20,147.76,146.66,135.53,132.02,128.45,128.04,127.97,127.78,127.57,126.81,126.49 ,126.38,125.47,114.47,89.81,86.06,78.45,73.25,69.89,59.26,36.40,26.70,19.25,19.08,18.85; ESI-MS(m / z)767.39[MH] - .

[0251] 45

[0252] At room temperature, DDQ (885 mg, 3.9 mmol) was added to a mixture of nucleoside derivative 44 (1.0 g, 1.3 mmol) in 16 mL of dichloromethane-water (20:1). The mixture was allowed to react at room temperature for 24 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). The reaction solution was concentrated under reduced pressure, extracted with ethyl acetate, washed sequentially with saturated sodium sulfite solution, sodium bicarbonate solution, and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was dissolved in 10 mL of tetrahydrofuran, and triethylamine (453 μL, 3.25 mmol) and triethylamine trihydrofluoride (636 μL, 3.9 mmol) were added sequentially. The reaction was allowed to react at room temperature for 12 h. The reaction was complete by TLC (dichloromethane / methanol = 10 / 1). 700 mg of solid sodium bicarbonate was added to the reaction solution, and the mixture was stirred until no bubbles were generated. The reaction solution was concentrated under reduced pressure and directly purified by flash column (gradient elution: dichloromethane / methanol = 0-25%) to obtain 380 mg of cyano-locked nucleoside 45 with a yield of 75%. 1 H NMR(MeOH-d4,400MHz)δ8.03(s,1H),5.91(s,1H),4.88(s,1H),4.78(s,1H),4.45(s,1H),4.17(s,2H),2.74-2.67(m,1H),1.23(d,J=6.9Hz,6H); 13 C NMR(MeOH-d4,100MHz)δ181.72,150.01,149.42,137.97,121.52,116.12,91. 68,87.21,82.33,71.84,70.25,57.76,36.36,19.28; ESI-MS(m / z)389.09[MH] - .

[0253] 46

[0254] To a solution of cyano-locked nucleoside 45 (300 mg, 0.77 mmol) in 5 mL of pyridine was added 4,4'-dimethoxytrityl chloride (390 mg, 1.15 mmol) at room temperature and stirred at room temperature for 12 h. The reaction was complete by TLC (dichloromethane / MeOH = 5 / 1). The reaction was quenched with 2 mL of methanol and concentrated under reduced pressure. The residue was diluted with ethyl acetate, washed sequentially with water and saturated brine, dried over Na2SO4, concentrated, and purified by flash column chromatography (gradient elution: methanol / dichloromethane = 0-10%) to afford 520 mg of 5'-O-DMTr-protected cyano-locked nucleoside 46 as a slightly yellow foamy solid in a 97% yield. 1 H NMR(DMSO-d6,400MHz)δ12.13(s,1H),11.86(s,1H),8.06(s,1H),7.45-7.22(m,9H),8.91(d,J=8.8Hz,4H),6.29(d,J=3.5Hz,1H),5.95(s,1H),5.2 9(s,1H),4.75(s,1H),4.48(d,J=3.5Hz,1H),3.86(d,J=11.2Hz,1H),3.74 (s,6H),3.46(d,J=11.2Hz,1H),2.82-2.75(m,1H),1.13(d,J=6.8Hz,6H); 13 C NMR(DMSO-d6,100MHz)δ180.74,158.67,155.20,148.86,145.08,136.74,135.82,135.37,130.26,130.21,128.35,128.11,127 .29,120.82,115.96,113.72,113.68,81.22,86.29,80.07,71.35,69.42,60.01,55.52,35.24,19.31; ESI-MS(m / z)691.36[MH] - .

[0255] 47

[0256] To a solution of guanosine 46 (380 mg, 0.55 mmol) and 2-cyanoethyl N,N,N',N'-tetraisopropylphosphoramidite (330 mg, 1.1 mmol) in 10 mL of dichloromethane was added 1H-tetrazole (31 mg, 0.44 mmol) at room temperature. The reaction was allowed to react for 6 h at room temperature. TLC analysis indicated that the reaction was complete (dichloromethane / ethyl acetate = 2 / 1). The reaction solution was directly purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-50%) to afford 380 mg of phosphoramidite 47 as a slightly yellow waxy solid in a 77% yield. 31PNMR(152MHz,DMSO-d6)δ149.69,149.09; ESI-MS(m / z)891.42[MH] - .

[0257] S-6'-CN-LNA- m Synthesis of C phosphoramidite monomer

[0258] The reaction conditions are as follows: (a) (1) TESCl, Et3N, acetonitrile, 0℃-room temperature, 3h; (2) 1,2,4-triazole, POCl3, acetonitrile, 0℃-room temperature, 2h; (3) NH4OH, 1,4-dioxane, room temperature, 2h; (b) (1) Bz2O, acetonitrile, room temperature, 20h; (2) TBAF, THF, room temperature, 12h; (c) 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite, 1H-tetrazole, dichloromethane, room temperature, 5h.

[0259] 48

[0260] To a solution of thymidine 37 (3.4 g, 5.69 mmol) and triethylamine (15.8 mL, 113.8 mmol) in acetonitrile (50 mL) at 0°C was added triethylsilyl chloride (4.78 mL, 28.45 mmol) and stirred at room temperature for 3 h. 1,2,4-Triazole (5.9 g, 85.35 mmol) was added to the reaction solution, and stirring continued for 10 min. POCl₃ (1.6 mL, 17.07 mmol) was then added dropwise at 0°C. The reaction mixture was allowed to react at room temperature for 2 h. The reaction solution was poured into 300 mL of ice water, extracted with ethyl acetate, washed sequentially with water, saturated NaHCO₃, and saturated brine, dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was dissolved in 30 mL of 1,4-dioxane and aqueous ammonia (4.25 mL) was added. The mixture was stirred at room temperature for 2 h. The reaction solution was concentrated under reduced pressure, extracted with ethyl acetate, washed with water and saturated brine, dried over anhydrous Na2SO4, filtered, concentrated, and purified by flash column (gradient elution: methanol / dichloromethane = 0-15%) to obtain 3.9 g of aminonucleoside 48 as a light yellow solid, with a yield of 96%. 1 H NMR(DMSO-d6,400MHz)δ7.50-7.44(m,4H),7.37-7.25(m,8H),6.93(d,J=8.6Hz,4H),5.55(s,1H),5.09(s,1H),4.46(s,1H), 4.35(s,1H),3.75(s,6H),3.68(d,J=11.2Hz,1H),3.53(d,J=11.2Hz,1H),1.70(s,3H),0.81-0.74(m,9H),0.55-0.43(m,6H);13 C NMR(DMSO-d6,100MHz)δ166.07,158.80,158.77,154.96,144.83,136.61,135.63,135.18,130.24,130.08,128.43,128.03,127.4 4,115.51,113.76,101.81,88.80,87.37,86.49,80.72,71.31,69.03,58.57,55.55,13.94,6.75,4.45; ESI-MS(m / z)733.31[M+Na] + .

[0261] 49

[0262] To a solution of aminonucleoside 48 (3.9 g, 5.49 mmol) in acetonitrile (20 mL) was added benzoic anhydride (2.73 g, 12 mmol). After stirring at room temperature for 20 h, the reaction was quenched by adding 5 mL of water. TBAF (3.47 g, 11 mmol) was added to the reaction mixture, and the reaction was allowed to proceed at room temperature for 12 h. 15% NaOH was then added to adjust the pH to 10 and stirring was continued for 3 h. The mixture was extracted with ethyl acetate, washed sequentially with water and saturated brine, dried over anhydrous Na2SO4, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-40%) to afford 3.2 g of nucleoside 49 as a white foamy solid in 83% yield. 1 H NMR(DMSO-d6,400MHz)δ13.08(s,1H),8.21(d, J=7.6Hz,1H),7.62-7.27(m,12H),6.95(d,J=8.6Hz,4H),6.40(d,J=3.2Hz,1H),5.61(s,1H),5.18(s,1H),4 .57(s,1H),4.31(d,J=3.2Hz,1H),3.86(d,J=11.2Hz,1H),3.76(s,6H),3.53(d,J=11.2Hz,1H),1.86(s,3H); 13 C NMR(DMSO-d6,100MHz)δ178.62,170.82,159.46,147.48,145.03,137.25,137.10,135.30,130.31,130.25,129.86,128.80,128.46, 128.12,127.39,115.87,113.78,110.13,89.52,87.06,86.50,80.60,70.34,69.06,59.99,55.55,13.62; ESI-MS(m / z)701.32[M+H]+ .

[0263] 50

[0264] To a solution of nucleoside 49 (2.3 g, 3.28 mmol) and 2-cyanoethyl N,N,N',N'-tetraisopropylphosphoramidite (1.2 g, 3.93 mmol) in 25 mL of anhydrous dichloromethane was added 1H-tetrazole (230 mg, 3.28 mmol) and allowed to react at room temperature for 5 h. Saturated NaHCO3 solution was added to the reaction solution, which was extracted with dichloromethane, washed with saturated brine, dried over anhydrous MgSO4, filtered, concentrated, and purified by flash column chromatography (gradient elution: ethyl acetate / dichloromethane = 0-20%) to afford 2.13 g of phosphoramidite 50 as a white foamy solid in a 72% yield. 31 P-NMR(152MHz,DMSO-d6)δ149.23,147.95; ESI-MS(m / z)901.46[M+H] + .

[0265] Experimental Example 1: Cyano-Locked Nucleic Acid Modified ASO-Protein Interaction

[0266] Experimental methods

[0267] Thermal denaturation test (T m value)

[0268] Annealing buffer: 10mM Na3PO4, 100mM NaCl, pH 7.2. Annealing method: Dilute the two oligonucleotide single strands with annealing buffer to a final concentration of 2μM, heat in a 95℃ water bath for 5 minutes, slowly cool to room temperature, and place in a 4℃ refrigerator overnight. Tm determination method: Add 100μL of the sample to be tested to the cuvette and cover it with a heat-insulating lid. Use 15℃ as the starting temperature and 90℃ as the ending temperature. The temperature rise rate is 0.5℃ / min, and the A260 reading rate is 1 time / ℃. The instrument will finally output the Tm value. m Each sample was measured three times and the average value was taken as the final result.

[0269] Immunofluorescence experiments:

[0270] 1) Cell preparation: The day before, HeLa cells were seeded into a 20 mm diameter confocal culture dish at a cell density of 2 × 10 5 The 20 mm confocal culture dish was then placed in a CO2 incubator for culture.

[0271] 2) Preparation of PS-ASOs: Dissolve ON1, ON2, and ON3 powders into a 100 μM solution in RNase- and DNase-free water.

[0272] 3) Transfection: Pipette 10 μL of Lipofectamine 2000 (Solybo) and add Prepare 250 μL of transfection reagent in medium. Then, mix thoroughly with 250 μL of Lipofectamine 2000 diluent at a transfection volume of 4 μg / dish. After 5 minutes, add 500 μL of this mixture to each dish. Aspirate the transfection reagent mixture and wash the cells three times with PBS. Then, add 500 μL of DMEM (Sigma) to each well as a maintenance medium. Place the 20 mm confocal microplates in a CO2 incubator and transfect for 5 minutes, 2 hours, and 4 hours, respectively.

[0273] 4) Fixation: discard the waste solution, wash the cells three times with PBS, and then fix them with 4% paraformaldehyde at room temperature for 30 minutes, and then permeabilize them with 0.1% Triton X-100 (prepared with PBS) for 5 minutes.

[0274] 5) Blocking: The fixed cells were blocked with blocking buffer (prepared with 1 mg / ml BSA and PBS) at room temperature for 30 min.

[0275] 6) Primary antibody binding: dilute the primary antibody (NONO, Cell signaling) in blocking buffer, incubate at room temperature for 1 hour, then place in a 4°C refrigerator overnight, and wash three times with washing buffer (0.1% Tween in PBS, wash every 5 minutes).

[0276] 7) Secondary antibody binding: Dilute the secondary antibody (Anti-rabbit IgG, Cell signaling) in blocking buffer, incubate at room temperature for 1 hour, and finally wash the cells three times with washing buffer.

[0277] 8) Sealing and detection: Prolong antifade reagent (Cell signaling) containing 4′,6-diamidino-2-phenylimidazoline (DAPI) was added dropwise to the culture dish, and the cells were observed and photographed using an inverted fluorescence microscope.

[0278] Caspase 3 / 7 activity assay

[0279] 1) Cell preparation: HeLa cells (Beina Biotech) were seeded into 96-well cell culture plates the day before, with a cell density of 5×10 4 The 96-well cell culture plate was then placed in a CO2 incubator for culture.

[0280] 2) Preparation of PSASOs: Dissolve ON1, ON2, and ON3 powders into 10 μM solution in RNase- and DNase-free water. Medium (Thermofisher) was used to dilute 10 μM ON1, ON2, and ON3 solutions into 1000 nM, 500 nM, 250 nM, 125 nM, 62.5 nM, and 0 nM solutions.

[0281] 3) Transfection: Pipette 2 μL of Lipofectamine 2000 (Thermofisher) and add Prepare 100 μL of transfection reagent in the medium. Then, pipette 100 μL of PSASO solutions of varying concentrations and mix thoroughly with 100 μL of Lipofectamine 2000 dilution. After 5 minutes, add 50 μL of this mixture to each well. Four hours after transfection, remove the transfection reagent mixture and wash three times with PBS. Then, add 100 μL of DMEM (Thermofisher) to each well as a cell maintenance medium, and place the 96-well cell culture plate in a CO2 incubator for an additional 8 hours.

[0282] 4) Detection: The 96-well cell plate was removed from the CO2 incubator, and 100 μL of Caspase-Glo 3 / 7 Reagent (Promega) was added to each well. After incubation for 30 min, the luminescence signal of each well was read using a multi-function fluorescence microplate reader (Promega).

[0283] Experimental content

[0284] Intracellular ASO-protein interactions are closely related to the druggability of PS-ASOs. Differences in chemical modifications will significantly affect ASO-protein interactions, thereby affecting the subcellular distribution of bound proteins and inducing cell apoptosis toxicity. In order to detect the effect of cyano-locked nucleic acid modification on the interaction between ASO and intracellular proteins, the inventors selected the toxic 3-10-3 gapmer PS ASO sequence 449093 (5'-TTCAGTCATGACTTCC-3' (SEQ ID NO.1)) reported in the literature as the template sequence (Nature Biotech., 2019, 37, 640) for study. By combining the corresponding T and m C, ON1 and ON2 were synthesized by introducing them into 449093 at both ends via the solid-phase phosphoramidite method, and 449093 (ON3) was modified with LNA for comparison. The mass spectrometry identification data are shown in Table 1, and the corresponding mass spectra are shown in Figures 1-3.

[0285] First, the hybridization properties of ON1-3 with the target RNA were determined, and their Tm values ​​were 67.04℃, 63.96℃, and 66.59℃, respectively, indicating that compared with the LNA-modified PS ASO ON3, the CN-LNA-modified PS-ASOs ON1-2 can still maintain good affinity with the target RNA.

[0286] Secondly, using intracellular paraplakin protein P54nrb as a model protein, the effects of cyano-locked nucleic acid modification on the interaction between ASOs and intracellular proteins were investigated. Paraplakin protein P54nrb can bind to toxic ASOs (with low nanomolar affinity), altering their distribution and causing them to accumulate in the nucleolus. This effect is significant and positively correlated with ASO toxicity. The experimental results are measured by the accumulation of paraplakin protein P54nrb in the nucleolus.

[0287] Cells were transfected with ON1, ON2, and ON3 for 5 min, 2 h, and 4 h, respectively. The localization of P54nrb protein was observed under an inverted fluorescence microscope and photographed. As shown in Figure 4 (scale bar: 10 μm), the results showed that: (1) at 5 min, the distribution of P54nrb in the nucleus was the same as that of the blank control, with clear nucleoli and uniform distribution of P54nrb in the nucleus. LNA and CN-LNA modified ASO did not change the distribution of P54nrb, and no aggregation in the nucleolus was observed; (2) for the LNA group, when the incubation time was extended to 2 h and 4 h, significant P54nrb aggregation occurred in the LNA group. The longer the incubation time, the more aggregation in the nucleolus, indicating that LNA modified ASO has a strong binding affinity with intracellular proteins, which can easily interfere with the normal distribution and function of intracellular proteins and produce toxic side effects. (3) From the perspective of the R-CN-LNA group, at 2 h, the R-CN-LNA modified sequence ON1 showed no obvious aggregation of P54nrb protein in the nucleolus, and the red fluorescence was evenly distributed in the cell nucleus. However, at 4 h, some cells showed obvious aggregation of P54nrb, but it was obvious that the degree of aggregation was significantly lower than that of the LNA group at the corresponding time point; (4) Regardless of 2 h or 4 h, the S-CN-LNA group showed no visible changes in the distribution of P54nrb at any time point, and P54nrb was still evenly distributed in the cytoplasm.

[0288] Table 1 Oligonucleotide sequences ON1-4 and their corresponding mass spectrometry data

[0289] Based on the current immunofluorescence experiments, to further quantify the effects of LNA, R-CN-LNA, and S-CN-LNA modifications on the nuclear distribution of P54nrb, we statistically analyzed the percentage of cells showing "significant accumulation" of P54nrb in the nucleolus at 10 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours in the LNA, R-CN-LNA, and S-CN-LNA groups, respectively. As shown in Table 2, the number of cells showing significant nucleolus accumulation of P54nrb increased with increasing transfection time in the LNA group. At 4 hours after LNA transfection, approximately 92% of transfected cells showed significant nucleolus accumulation of P54nrb. In the R-CN-LNA group, P54nrb showed significant nucleolus accumulation in only 5% of cells at 2 hours after ASO transfection, and only about 8% at 4 hours. In the S-CN-LNA group, no P54nrb accumulation was observed, with the percentage of cells showing significant nucleolus accumulation being 0%. The above results show that compared with LNA modification, CN-LNA modification can indeed reduce the impact of ASO on intracellular proteins, and the S configuration has less impact and is better than the R configuration.

[0290] Table 2 The percentage of cells in which P54nrb was significantly accumulated in the nucleolus by LNA-ASO, R-CN-LNA-ASO and S-CN-LNA-ASO

[0291] Based on the above evaluation of the effect on the subcellular distribution of intracellular proteins, the effect of CN-LNA modification on the induction of cell apoptosis toxicity was further investigated by detecting Caspase 3 / 7 activity in HeLa cells.

[0292] Cells were transfected with ON1, ON2, and ON3 at concentrations of 500nM, 250nM, 125nM, 62.5nM, 31.25nM, and 0nM, respectively. After 4 hours of transfection, cells were incubated for another 8 hours, and caspase 3 / 7 activity was detected by fluorescence microplate reader. As shown in Figure 5, the experimental results showed that: (1) at low concentrations (0-62.5nM), no significant changes in caspase activity were observed in the three groups; (2) starting from 125nM, the caspase activity level of the LNA-modified group increased rapidly with increasing drug concentration, while the two CN-LNA-modified groups only began to increase slowly from 250nM, and the S-configuration was lower than the R-configuration; (3) at high concentrations of 250nM and 500nM, compared with LNA modification, both R-CN-LNA and S-CN-LNA modifications could reduce the increase in caspase activity by more than 2 times, and the S-configuration was superior to the R-configuration. The above results show that compared with LNA modification, R / S-CN-LNA modification can significantly reduce the apoptotic toxicity induced by PS ASO, which is consistent with the results of immunofluorescence experiments.

[0293] In summary, the introduction of cyano groups into LNA can reduce the lipophilicity of LNA and improve the water solubility of the modified structure. The cyano-locked nucleic acid modification can significantly reduce the effect of PS ASO on intracellular proteins and induce cell apoptosis toxicity, thereby improving the therapeutic effect of PSASO. It has significant application value for nucleic acid drugs and can provide a new generation of chemical modification technology support for nucleic acid drugs.

[0294] Test Example 2 Nuclease resistance experiment of S-CN-LNA-T

[0295] Nuclease stability is a key parameter for chemical modification of nucleotides. This experiment used snake venom phosphodiesterase (SVPDE) to investigate the nuclease resistance of the S-CN-LNA-T-modified oligonucleotide ON4 (5'-TTTTTTTTTT-3' (SEQ ID NO. 2), T = S-6'-CN-LNA). Comparisons were made with R-CN-LNA (ON5), LNA (ON6), thio-modified (ON7), and native (ON8) sequences. The corresponding nucleic acid sequences (7 nM) were enzymatically digested with SVPDE (1.0 μg / mL) at 37°C in a 50 mM Tris-HCl, 10 mM MgCl2, pH 8.0 buffer system. Incubation solutions were removed at various time points (0, 2, 5, 10, 20, 30, and 40 min) and quantified by HPLC to generate corresponding content-time curves. The results of the nuclease resistance experiment (Figure 7, where T = S-CN-LNA (rectangle) modification ON4, R-CN-LNA (diamond) modification ON5, LNA (triangle) modification ON6, 3'-thio-T (Ts, cross) modification ON7, and natural T (Natural-T, star) modification ON8) showed that under 1.0 μg / mL SVPDE conditions, the R-6'-CN-LNA modified sequence ON7 degraded slowly, with more than 40% still undegraded after 40 minutes. The S-6'-CN-LNA modified sequence ON8 had more than 50% undegraded, while the LNA modified sequence had less than 10% remaining. This indicates that 6'-CN-LNA can significantly improve the nuclease resistance of oligonucleotides, significantly better than LNA, and that the S configuration is superior to the R configuration.

[0296] Clearly, despite its relatively small size, the cyano group can still enhance the stability of LNA against nucleases, which is consistent with the results of other C6'-modified LNAs. It is worth noting that the R and S configurations of cEt-LNA reported in the literature have similar nuclease resistance, while for CN-LNA, the S configuration is more resistant to nucleases than the R configuration. Considering that the cyano group in the S configuration is oriented toward the phosphate, this seems to indicate that CN has a more complex effect on the phosphate. If so, it will have a greater impact on the interaction between CN-LNA-modified ASOs and proteins, not just electrostatic interactions.

[0297] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. 6'-Cyanide-modified locked nucleoside, It is characterized in that The 6'-cyano modified locked nucleoside is selected from a compound having a structure as shown in Formula 1, a salt thereof or an isomer thereof: In Formula 1: Bx is selected from substituted or unsubstituted: adenine, guanine, thymine, cytosine, uracil or their respective salts; Z is a cyano group; W 1 and W 2 independently selected from H or a hydroxyl protecting group; the hydroxyl protecting group includes: acetyl, tert-butyl, tert-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, di(2-acetoxyethoxy)methyl, 2-trimethylsilylethyl, trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tritylsilyl, [(triisopropylsilyl)oxy]methyl, benzoylformate, chloroacetyl, trichloroacetyl, trifluoroacetyl, pivaloyl, benzoyl, p-phenylbenzoyl, 9-fluorenylmethyl carbonate, methanesulfonate, p-toluenesulfonate, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, 1(2-fluorophenyl)-4-methoxypiperidin-4-yl, 9-phenylxanthin-9-yl, 9-(p-methoxyphenyl)xanthin-9-yl, or 2-naphthylmethyl; The isomers include: 6'-cyano modified locked nucleoside with the Z group in R configuration, the structural formula is Or the Z group is in S-configuration 6'-cyano modified locked nucleoside, the structural formula is 2. The 6'-cyano modified locked nucleoside according to claim 1, It is characterized in that The 6'-cyano modified locked nucleoside in which the Z group is in R configuration is The 6'-cyano modified locked nucleoside in which the Z group is in S configuration is 3. Nucleotides, It is characterized in that The nucleotide comprises a 3'-active phosphorus group derivative of the 6'-cyano modified locked nucleoside according to claim 1 or 2; The active phosphorus group is selected from phosphoramidites, derivatives of phosphoramidites, H-phosphates, derivatives of H-phosphates, phosphotriesters, or derivatives of phosphotriesters.

4. The nucleotide according to claim 3, It is characterized in that The nucleotide is selected from a compound having a structure as shown in Formula 2, a salt thereof or an isomer thereof: In formula 2: Bx, W 2 and the types of Z are the same as in Formula 1; The isomers include: nucleotides with the Z group in R configuration, with the structural formula Or the nucleotide with Z group in S configuration has the structural formula 5. The nucleotide according to claim 4, It is characterized in that The nucleotide in which the Z group is in the R configuration is The nucleotide in which the Z group is in the S configuration is 6. Use of the nucleotide according to claim 3, 4 or 5 in reducing the interaction between nucleic acid polymers and intracellular proteins or in the preparation of a drug for reducing the interaction between nucleic acid polymers and intracellular proteins.

7. Use of the nucleotide according to claim 3, 4 or 5 in regulating the interaction between nucleic acid polymers and intracellular proteins or in preparing a drug for regulating the interaction between nucleic acid polymers and intracellular proteins.

8. Nucleic acid polymers, It is characterized in that The nucleic acid polymer has a monomer having a structure as shown in Formula 3: In Formula 3, Bx is selected from substituted or unsubstituted: adenine, guanine, thymine, cytosine, uracil or their respective salts; Z is a cyano group; W 3 and W 4 Each independently is H, a hydroxyl protecting group or an internucleoside linking group that connects the monomer to the rest of the nucleic acid polymer; and at least W 3 and W 4 One is an internucleoside linking group that connects the monomer to the rest of the nucleic acid polymer; The hydroxy protecting groups include: acetyl, tert-butyl, tert-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, di(2-acetoxyethoxy)methyl, 2-trimethylsilylethyl, trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tritylmethylsilyl , [(triisopropylsilyl)oxy]methyl, benzoylformate, chloroacetyl, trichloroacetyl, trifluoroacetyl, pivaloyl, benzoyl, p-phenylbenzoyl, 9-fluorenylmethyl carbonate, methanesulfonate, p-toluenesulfonate, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl, 1(2-fluorophenyl)-4-methoxypiperidin-4-yl, 9-phenylxanthine-9-yl, 9-(p-methoxyphenyl)xanthine-9-yl or 2-naphthylmethyl.

9. The nucleic acid polymer according to claim 8, It is characterized in that The monomers include: monomers with a Z group in R configuration, with the structural formula Or the monomer with Z group in S configuration has the structural formula 10. The nucleic acid polymer according to claim 9, It is characterized in that The nucleic acid polymer is ribonucleic acid, deoxyribonucleic acid or a copolymer of ribonucleotide and deoxyribonucleotide.

11. Use of the nucleic acid polymer according to any one of claims 8 to 10 in the preparation of a nucleic acid diagnostic agent or a nucleic acid therapeutic agent.

12. A method for synthesizing a C6'-cyano-modified nucleoside of R or S configuration, It is characterized in that The R-configuration C6'-position cyano-modified nucleoside is The synthesis method comprises: Isomerization of terminal olefins to obtain Then the dihydroxylation reaction was carried out to obtain Then, the aldehyde compound is obtained through oxidative cleavage reaction. Finally The aldehyde group of the nucleoside was converted into a cyano group to obtain a C6'-position cyano-modified nucleoside with R configuration. S-configuration C6'-position cyano-modified nucleosides are The synthesis method comprises: Isomerization of terminal olefins to obtain Then the dihydroxylation reaction was carried out to obtain Then, the aldehyde compound is obtained through oxidative cleavage reaction. Finally The aldehyde group of the nucleoside was converted into a cyano group to obtain a S-configuration C6'-position cyano-modified nucleoside. Wherein, Bx is selected from substituted or unsubstituted: adenine, guanine, thymine, cytosine, uracil or their respective salts.

13. The synthesis method according to claim 12, It is characterized in that Said The synthesis method comprises: The mesylation reaction, debonding reaction and acetylation reaction were carried out in sequence to obtain Then, glycosylation and nucleophilic substitution reactions were performed to synthesize the R configuration. Said The synthesis method comprises: The mesylation reaction, debonding reaction and acetylation reaction were carried out in sequence to obtain Then glycosylation reaction and nucleophilic substitution reaction are carried out to synthesize the S configuration The glycosidation reaction is as follows: under the condition of an activating agent, The method comprises reacting with thymine, N6-benzoyl adenine or 6-chloroguanine at 50-100° C., wherein the activating agent comprises BSA and TMSOTf, and the reaction medium comprises acetonitrile, 1,2-dichloroethane or toluene.

14. The synthesis method according to claim 13, It is characterized in that The S configuration The synthesis method comprises: 5-O-(tert-butyldiphenylsilyl)-4-C-hydroxymethyl-1,2-O-isopropylidene-3-O-(2-naphthylmethyl)-α-D-ribofuranose The primary alcohol is oxidized to an aldehyde group, and then the aldehyde group is allylated to obtain the S configuration. The R configuration The synthesis method comprises: The secondary alcohol is oxidized to a ketone, and then the ketone is reduced to a secondary alcohol to obtain the R configuration. In the process of reducing ketone to secondary alcohol: the reducing agent used includes at least one of lithium aluminum hydride, lithium borohydride, lithium chloride or sodium borohydride, the reaction medium includes at least one of dichloromethane, tetrahydrofuran, methanol or ethanol, and the reaction temperature is -78-0°C; 15. The synthesis method according to claim 14, It is characterized in that The reaction method for reducing ketone to secondary alcohol is: using sodium borohydride and lithium chloride as reducing agents, tetrahydrofuran and methanol as reaction media, and reacting at -40-0°C.

16. The synthesis method according to claim 12, It is characterized in that The catalyst for the isomerization of terminal olefins includes a ruthenium catalyst, a palladium catalyst, a rhodium catalyst or an iridium catalyst; The reaction medium for the terminal olefin isomerization includes methanol, ethanol, n-butanol or toluene; The reaction temperature of the terminal olefin isomerization is 60-100°C; The reaction time of the terminal olefin isomerization is 12-72 hours.

17. The synthesis method according to claim 12, It is characterized in that The catalyst for the terminal olefin isomerization is tris(triphenylphosphine)carbonylruthenium(II) hydrochloride; the reaction medium for the terminal olefin isomerization is ethanol; and the reaction temperature for the terminal olefin isomerization is 60-80°C.

18. A method for synthesizing a R-configuration or S-configuration C6'-position cyano-locked nucleic acid T phosphoramidite monomer, It is characterized in that The method for synthesizing an R-configuration C6'-position cyano-locked nucleic acid T phosphoramidite monomer comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramidated to obtain the R configuration. The preparation method of the S-configuration C6'-position cyano-locked nucleic acid T phosphoramidite monomer comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramidated to obtain the S configuration.

19. A method for synthesizing a phosphoramidite monomer of a C6'-position cyano-locked nucleic acid A with R or S configuration, It is characterized in that The method for synthesizing the R-configuration C6'-position cyano-locked nucleic acid A phosphoramidite monomer comprises: The bases are protected to obtain Then the 3'-hydroxyl and 5'-hydroxyl groups are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramidated to obtain the R configuration. The method for synthesizing an S-configuration C6'-position cyano-locked nucleic acid A phosphoramidite monomer comprises: The bases are protected to obtain Then the 3'-hydroxyl and 5'-hydroxyl groups are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramidated to obtain the S configuration.

20. A method for synthesizing a C6'-position cyano-locked nucleic acid G phosphoramidite monomer of R or S configuration, It is characterized in that The method for synthesizing an R-configuration C6'-position cyano-locked nucleic acid G phosphoramidite monomer comprises: Demethylation of the methoxy group yields Then base protection was performed to obtain Then, the 3'-hydroxyl group and the 5'-hydroxyl group are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramidated to obtain the R configuration. The method for synthesizing an S-configuration C6'-position cyano-locked nucleic acid G phosphoramidite monomer comprises: Demethylation of the methoxy group yields Then base protection was performed to obtain Then, the 3'-hydroxyl group and the 5'-hydroxyl group are deprotected to obtain The 5'-hydroxyl group was then protected by DMTr, and the 3'-hydroxyl group was phosphoramidated to obtain the S configuration.

21. A method for synthesizing an R-configuration or S-configuration C6'-position cyano-locked nucleic acid C phosphoramidite monomer, It is characterized in that The method for synthesizing an R-configuration C6'-position cyano-locked nucleic acid C phosphoramidite monomer comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain Then the 5'-hydroxyl group was protected by DMTr to obtain The 3'-hydroxyl group is then silylated and the carbonyl group is converted into an amino group to obtain Then, base protection is performed and the 3'-hydroxyl group is deprotected to obtain Finally, the 3'-hydroxyl group was phosphoramidated to obtain the R configuration. The method for synthesizing an S-configuration C6'-position cyano-locked nucleic acid C phosphoramidite monomer comprises: The 3'-hydroxyl group and the 5'-hydroxyl group were deprotected to obtain Then the 5'-hydroxyl group was protected by DMTr to obtain The 3'-hydroxyl group is then silylated and the carbonyl group is converted into an amino group to obtain Then, base protection is performed and the 3'-hydroxyl group is deprotected to obtain Finally, the 3'-hydroxyl group was phosphoramidated to obtain the S configuration.

22. A method for synthesizing a nucleic acid polymer, It is characterized in that The monomers are polymerized to prepare nucleic acid polymers; The monomer comprises the 6'-cyano modified locked nucleoside according to claim 1 or 2 or the nucleotide according to claim 3, 4 or 5.

Citation Information

Patent Citations

  • 6 '-cyano modified locked nucleosides, nucleotides and nucleic acid polymers

    CN116606338A

  • Synthesis of bicyclic nucleosides

    CN106459135A

  • Modified nucleoside, nucleotide and modified nucleic acid polymer as well as preparation method and application thereof

    CN110204583A

  • Modified nucleoside, nucleotide, nucleic acid polymer, preparation method of modified nucleoside and application of nucleic acid polymer

    CN110590886A